{"gene":"SLC1A5","run_date":"2026-06-10T07:46:32","timeline":{"discoveries":[{"year":2018,"finding":"Cryo-EM and crystal structures of ASCT2/SLC1A5 revealed that substrate recognition involves conformational changes in the HP2 loop, the ECL2a loop connects the scaffold and transport domains enabling rigid body movement during the transport cycle, and a putative cholesterol binding site exists near the domain interface in the outward-facing state. Comparison with the inward-facing structure provided a mechanistic basis for the transport cycle.","method":"Cryo-EM structure determination; substrate co-complex structures","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1 / Strong — cryo-EM structures of human SLC1A5 in outward-facing conformation with and without substrate, multiple orthogonal structural approaches","pmids":["31580259"],"is_preprint":false},{"year":2018,"finding":"Crystal structures of a prokaryotic ASCT2 homologue bearing mutations at two substrate-binding residues identified in ASCT2 revealed the structural basis for glutamine (neutral amino acid) selectivity and inhibitor binding in the SLC1 family; these two residues confer glutamine selectivity unique to ASCT2 among SLC1 family members.","method":"Site-directed mutagenesis of substrate-binding residues; crystal structure determination of prokaryotic homologue","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — four crystal structures with mutagenesis validating functional relevance of identified residues","pmids":["29295993"],"is_preprint":false},{"year":2021,"finding":"Rational design using cryo-EM structures and molecular dynamics simulations identified stereospecific ASCT2 inhibitors exploiting specific subpockets in the substrate binding site, revealing multiple pharmacologically relevant conformations and a previously unknown mechanism of stereospecific inhibition.","method":"Cryo-EM; molecular dynamics simulations; electrophysiology transport assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — integrated cryo-EM structures with MD simulations and functional validation of inhibitor mechanism","pmids":["34507995"],"is_preprint":false},{"year":2013,"finding":"Purified human ASCT2 reconstituted in proteoliposomes demonstrated Na+-dependent glutamine/glutamine antiport activity with functional and kinetic asymmetry: external Km for glutamine (0.097 mM) was ~18-fold lower than internal Km (1.8 mM); Ala, Cys, Val, Met were only inwardly transported while Gln, Ser, Asn, Thr were transported bi-directionally. Cys395 was identified as the only externally exposed cysteine and potential target of SH-reagent inhibition.","method":"Recombinant protein expression in Pichia pastoris; reconstitution in proteoliposomes; radiolabeled transport assays; homology modeling","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with detailed kinetic characterization, replicated in subsequent studies","pmids":["23756778"],"is_preprint":false},{"year":2014,"finding":"Kinetic analysis of purified ASCT2 in proteoliposomes established a random simultaneous transport mechanism for the Na+-glutamine antiport reaction. The transporter was cross-linked to a stable dimeric form. The transport reaction is electrogenic, with electrogenicity originating from external Na+. Internal Na+ exerts a stimulatory regulatory (not counter-transport) effect. PDZK1 scaffold protein interaction with hASCT2 was confirmed both in vitro and in vivo.","method":"Pseudo-bi-substrate kinetic analysis in proteoliposomes; chemical cross-linking; membrane potential imposition with valinomycin; co-immunoprecipitation","journal":"Amino acids","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with multiple mechanistic assays (kinetics, electrogenicity, oligomeric state, protein interaction) in single study","pmids":["25052780"],"is_preprint":false},{"year":2018,"finding":"Site-directed mutagenesis of all cysteine residues in hASCT2 identified Cys467 as critical for substrate binding and transport activity modulation: C467A mutant showed ~10-fold higher Km for glutamine and lost sensitivity to both DTE activation and methylmercury inhibition. Cys467 is located in the substrate binding region based on structural comparison with EAAT1.","method":"Cys-to-Ala site-directed mutagenesis; transport assays in proteoliposomes; bioinformatics structural comparison","journal":"International journal of molecular sciences","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic mutagenesis of all 8 Cys residues with functional assays in reconstituted system, single lab","pmids":["29495336"],"is_preprint":false},{"year":2015,"finding":"N-linked glycosylation at Asn163 and Asn212 is critical for ASCT2 trafficking to the plasma membrane. Double mutation N163/212Q produced unglycosylated protein that failed to traffic to the membrane, showed strongly increased endocytosis rate, and reduced transport activity in intact cells. Critically, intrinsic transport function of the mutant was not affected when reconstituted in liposomes, demonstrating glycosylation regulates membrane localization rather than transport mechanism per se.","method":"Site-directed mutagenesis; protein biotinylation assay; reversible biotinylation endocytosis assay; cycloheximide stability assay; brefeldin-based trafficking assay; radiolabeled transport assay in cells and proteoliposomes","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods in one study clearly dissecting glycosylation roles in trafficking vs. transport function","pmids":["25862406"],"is_preprint":false},{"year":2019,"finding":"A variant of SLC1A5 with an N-terminal mitochondrial targeting signal localizes to mitochondria and transports glutamine into mitochondria. HIF-2α mediates hypoxia-induced expression of this variant. Overexpression promotes glutamine-induced ATP production and glutathione synthesis, and confers gemcitabine resistance in pancreatic cancer cells.","method":"Mitochondrial fractionation; live-cell imaging; siRNA knockdown; metabolic assays; HIF-2α ChIP; xenograft models","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — subcellular fractionation plus functional assays demonstrating mitochondrial localization and consequences, multiple orthogonal methods","pmids":["31866442"],"is_preprint":false},{"year":2019,"finding":"Cholesterol stimulates ASCT2 transport activity by ~3-fold increase in Vmax without affecting Km for glutamine. Cholesterol physically binds to the protein near CARC/CRAC motifs and tryptophan residues; modification of tryptophan residues blocked cholesterol binding, and cholesterol presence impaired thiol reagent access to cysteines.","method":"Transport assays in proteoliposomes with cholesteryl hemisuccinate; computational docking; tryptophan modification; thiol-reagent competition assays","journal":"Frontiers in molecular biosciences","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro reconstitution with docking, but single lab and indirect binding evidence","pmids":["31709262"],"is_preprint":false},{"year":2003,"finding":"A hypervariable 21-amino acid sequence in the carboxyl-terminal portion of extracellular loop 2 (ECL2) of hASCT2 is critical for retroviral receptor function for RD114, BaEV, HERV-W, and type D primate retroviruses. N-linked oligosaccharides in the carboxyl-terminal region of ECL2 restrict viral infections; tunicamycin (N-glycosylation inhibitor) treatment or mutagenesis of N-glycosylation sites activated receptor function for all viruses in the interference group.","method":"hASCT2/mASCT2 chimera construction; site-directed mutagenesis; viral infection susceptibility assays; tunicamycin treatment","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic chimera and mutagenesis analysis with functional viral infection readouts, multiple constructs tested","pmids":["12584318"],"is_preprint":false},{"year":2001,"finding":"The truncated ASCT2 mRNA isoform encodes multiple protein isoforms with distinct amino termini initiated by leaky scanning at CUG and GUG codons. ASCT2 isoforms with short N-terminal truncations retained both amino acid transport and viral receptor activities, whereas an isoform lacking the first transmembrane domain (79-aa truncation) retained only viral receptor activity but not amino acid transport activity.","method":"Site-directed mutagenesis of initiation codons; cell-free translation; epitope-tagged protein analysis; amino acid transport assay; viral infection assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — deletion and site-directed mutagenesis with multiple functional readouts dissecting domains required for transport vs. receptor activity","pmids":["11350958"],"is_preprint":false},{"year":2016,"finding":"ASCT2 (SLC1A5) is physically associated with EGFR in a molecular complex in HNSCC cells. Cetuximab-mediated EGFR endocytosis downregulates ASCT2 in an EGFR expression-dependent manner, decreasing glutamine uptake and glutathione levels, thereby sensitizing cells to ROS-induced apoptosis. EGFR kinase inhibition (gefitinib) or siRNA knockdown of EGFR failed to sensitize cells to ROS-induced apoptosis.","method":"Co-immunoprecipitation; EGFR endocytosis assay; glutamine uptake assay; glutathione measurement; apoptosis assay; siRNA knockdown","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — reciprocal Co-IP showing complex with functional consequences, single lab","pmids":["27450723"],"is_preprint":false},{"year":2022,"finding":"DDR1 (discoidin domain receptor 1) interacts with SLC1A5 and regulates its protein stability through lysosome-dependent degradation. Loss of DDR1 decreased SLC1A5 levels and downstream mTORC1 signaling; lysosome inhibitors restored SLC1A5 regulation by DDR1.","method":"Co-immunoprecipitation; CHX stability assay; lysosomal inhibitor (NH4Cl) rescue; mTORC1 signaling assessment; xenograft model","journal":"Cellular oncology (Dordrecht, Netherlands)","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP with functional stability assays, single lab, identifies lysosomal degradation mechanism","pmids":["35089546"],"is_preprint":false},{"year":2022,"finding":"TRIM6 E3 ubiquitin ligase directly interacts with SLC1A5 and promotes its ubiquitination and proteasomal degradation, thereby inhibiting glutamine import, glutaminolysis, lipid peroxidation, and ferroptosis in lung cancer cells.","method":"Co-immunoprecipitation; ubiquitination assay; TRIM6 overexpression/knockdown; glutamine uptake assay; ferroptosis assays; xenograft model","journal":"Oxidative medicine and cellular longevity","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP and ubiquitination assays establish E3-substrate relationship, single lab","pmids":["36654781"],"is_preprint":false},{"year":2022,"finding":"ASCT2 in astrocytes binds to NLRP3 and aggravates astrocytic inflammasome-triggered neuroinflammation in Parkinson's disease models. Genetic ablation of astrocytic ASCT2 alleviated neuroinflammation and rescued dopaminergic neuron damage in vitro and in vivo.","method":"Co-immunoprecipitation (ASCT2-NLRP3 binding); conditional knockout in astrocytes; MPTP mouse model; in vitro MPP+/LPS-ATP challenge","journal":"Acta pharmaceutica Sinica. B","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP demonstrating ASCT2-NLRP3 complex with genetic loss-of-function phenotype, single lab","pmids":["36873178"],"is_preprint":false},{"year":2022,"finding":"Inhibition of ASCT2 induces hepatic stellate cell senescence by interfering with the IL-1α/NF-κB feedback loop; ASCT2 physically interacts with precursor IL-1α at Lys82 and is a direct target of glutaminolysis-dependent proinflammatory SASP signaling.","method":"Co-immunoprecipitation (ASCT2-pro-IL-1α interaction); genetic ASCT2 inhibition; in vitro senescence assays; mouse fibrosis model","journal":"Acta pharmaceutica Sinica. B","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP identifies ASCT2-IL-1α interaction, single lab with multiple readouts but not replicated","pmids":["36176909"],"is_preprint":false},{"year":2023,"finding":"CAIX (carbonic anhydrase IX) physically interacts with SLC1A5 and coordinately regulates redox homeostasis through the GSH/GPX4 axis. Inhibition of CAIX increases glutamine uptake via SLC1A5 and raises GSH levels; combined inhibition of CAIX and SLC1A5/glutamine metabolism induces ferroptosis in vitro and in vivo.","method":"Co-immunoprecipitation; glutamine uptake assays; GSH/lipid peroxidation measurements; in vivo tumor models","journal":"Molecular cancer therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP establishing CAIX-SLC1A5 complex with functional consequence, single lab","pmids":["37348875"],"is_preprint":false},{"year":2016,"finding":"Deletion of ASCT2 (SLC1A5) in HeLa and 143B cancer cells did not reduce net glutamine uptake or cell growth; instead, it activated a GCN2-dependent amino acid starvation response that upregulated SNAT1 (SLC38A1) to compensate. Combined silencing of GCN2 in the ASCT2-/- background reduced cell growth, demonstrating that net glutamine uptake requires SNAT1/SNAT2, not ASCT2 in these cell lines.","method":"CRISPR/TALEN-mediated ASCT2 deletion; radiolabeled amino acid uptake; GCN2 siRNA; growth assays; Western blot for stress response markers","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic deletion with epistasis analysis (GCN2 double knockout rescue), multiple orthogonal methods, replicated in subsequent work","pmids":["27129276"],"is_preprint":false},{"year":2018,"finding":"ASCT2 KO in colon (LS174T) and lung (A549) cancer cells reduced glutamine import by >60% but did not affect leucine uptake. ASCT2 KO strongly decreased tumor growth in vivo in both lines, but without triggering amino acid stress response (GCN2/EIF2α/ATF4) or altered mTORC1 (S6K1/S6) activity in contrast to LAT1 KO cells, indicating ASCT2-mediated tumor growth reduction is independent of LAT1 and independent of mTORC1 modulation in these contexts.","method":"CRISPR-Cas9 knockout; radiolabeled amino acid uptake assays; Western blot for mTORC1/GCN2 signaling; xenograft tumor models","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR KO in two cell lines with in vivo validation and pathway analysis, multiple orthogonal methods","pmids":["29326164"],"is_preprint":false},{"year":2022,"finding":"STAT3 regulates MYC expression in AML leukemia stem cells, which directly controls SLC1A5 transcription. Genetic inhibition of MYC or SLC1A5 phenocopied STAT3 inhibition in impairing oxidative phosphorylation. SLC1A5 inhibition reduced intracellular glutamine, glutathione, and TCA cycle metabolites, leading to reduced TCA cycle activity and OXPHOS inhibition.","method":"Genetic inhibition (shRNA/siRNA) of STAT3, MYC, and SLC1A5; metabolomics; OXPHOS measurement; primary human AML specimens","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis establishing STAT3→MYC→SLC1A5 axis with metabolic readouts in primary human specimens and multiple genetic approaches","pmids":["34525179"],"is_preprint":false},{"year":2014,"finding":"ATF4 and N-Myc coordinately activate ASCT2 transcription in MYCN-amplified neuroblastoma cells. ATF4 was identified as a novel regulator directly binding the ASCT2 promoter region to activate its expression in cooperation with N-Myc.","method":"ChIP; luciferase reporter assay; ASCT2 depletion with glutaminolysis measurement; proliferation/tumorigenesis assays","journal":"The Journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ChIP and luciferase reporter establish direct transcriptional activation, single lab","pmids":["25142020"],"is_preprint":false},{"year":2019,"finding":"SLC1A5 is a direct transcriptional target of c-Myc. Myc+/- heterozygous mice have decreased Slc1a5 expression, lower glutamine uptake, reduced mTORC1 activity, and elevated fatty acid oxidation via Cpt1a upregulation, establishing MYC→SLC1A5→mTORC1→FAO as a regulatory axis.","method":"Gene expression analysis in Myc+/- mice; glutamine uptake assays; mTORC1 activity measurement; Cpt1a expression analysis; ChIP (MYC binding to SLC1A5 promoter implied by prior work)","journal":"Aging cell","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — genetic model with multiple metabolic readouts, single lab, limited direct mechanistic validation of MYC-SLC1A5 promoter binding","pmids":["30909319"],"is_preprint":false},{"year":2024,"finding":"ATF4 directly activates SLC1A5 transcription in colorectal cancer cells, as demonstrated by increased luciferase activity of the SLC1A5 promoter upon ATF4 overexpression and increased SLC1A5 promoter enrichment in ChIP with anti-ATF4 antibody. SLC1A5 knockdown inhibited glutamine metabolism, glucose metabolism, and expression of glycolytic enzymes HK2 and PKM2.","method":"Luciferase reporter assay; chromatin immunoprecipitation (ChIP); ATF4 overexpression/knockdown; SLC1A5 knockdown with metabolic assays","journal":"Acta biochimica et biophysica Sinica","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ChIP and luciferase reporter establish direct transcriptional regulation, single lab","pmids":["39696988"],"is_preprint":false},{"year":2017,"finding":"MeCP2 and DNA methyltransferases (DNMTs) cooperate to methylate the miR-137 promoter, repressing miR-137 transcription and thereby derepressing ASCT2 expression and glutamine metabolism in cancer cells. miR-137 directly targets the ASCT2 3'UTR. Ectopic ASCT2 expression rescued miR-137-mediated suppression of tumorigenesis.","method":"Promoter methylation analysis; ChIP; miR-137 overexpression/knockdown; ASCT2 rescue experiments; glutamine metabolic analysis","journal":"Oncogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — multiple methods establishing epigenetic regulatory mechanism, single lab","pmids":["28692032"],"is_preprint":false},{"year":2018,"finding":"miR-137 negatively regulates ferroptosis by directly targeting SLC1A5, suppressing glutamine uptake and malondialdehyde accumulation. Ectopic miR-137 expression decreased SLC1A5 levels and reduced sensitivity to ferroptosis inducers erastin and RSL3 in melanoma cells.","method":"miR-137 ectopic expression; antagomir treatment; SLC1A5 3'UTR luciferase reporter; glutamine uptake; MDA measurement; in vivo xenograft","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct targeting validated by luciferase reporter with functional ferroptosis readouts, single lab","pmids":["29348676"],"is_preprint":false},{"year":2006,"finding":"GLAST/EAAT1-mediated glutamate uptake into astrocytes, when converted to glutamine by glutamine synthetase (GS), is a potent inducer of ASCT2 trafficking from cytosol to the plasma membrane. In differentiated human fetal astrocytes, glutamine (and to a lesser extent alanine) redistributed ASCT2 from cytosol to membrane; at lower pH (6.2–6.7), the cell surface pool of ASCT2 was larger. GS knockdown abolished the glutamate-induced effect on ASCT2 trafficking.","method":"siRNA knockdown of GS; immunofluorescence/subcellular localization of ASCT2; amino acid transport assays in human fetal astrocyte cultures; cAMP-induced differentiation","journal":"Neurochemistry international","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — siRNA epistasis with immunofluorescence establishing substrate-dependent trafficking mechanism, single lab","pmids":["16516348"],"is_preprint":false},{"year":2004,"finding":"ASCT2 promoter activity and protein expression in HepG2 hepatoma cells are dependent on glutamine availability: glutamine deprivation reduced both ASCT2 protein and promoter-driven luciferase activity; restoration of glutamine reversed these effects. Deprivation of other essential amino acids had no effect on promoter activity.","method":"Luciferase reporter assay with 907-bp ASCT2 5'-flanking sequence; Western blot for ASCT2 protein; glutamine deprivation/repletion experiments","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — luciferase reporter assay establishing glutamine-dependent promoter regulation, single lab","pmids":["15175006"],"is_preprint":false},{"year":2024,"finding":"ASCT2 (SLC1A5) functions as a major serine transporter in cancer cells, with serine and glutamine competing for uptake through ASCT2. ASCT2-mediated serine uptake is essential for purine nucleotide biosynthesis. Estrogen receptor α (ERα) promotes serine uptake by directly activating SLC1A5 transcription.","method":"ASCT2 knockout/knockdown; serine uptake assays; glutamine/serine competition assays; purine biosynthesis metabolomics; ERα ChIP on SLC1A5 promoter","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ASCT2 KO with multiple functional readouts (serine transport, purine biosynthesis, ERα ChIP), multiple orthogonal methods","pmids":["39068660"],"is_preprint":false},{"year":2021,"finding":"SLC1A5 provides both glutamine and asparagine to osteoblasts, which are essential for osteoblast differentiation. These amino acids primarily support biosynthesis of non-essential amino acids. Cell-autonomous loss of SLC1A5 impaired protein synthesis and osteoblast differentiation in a genetic mouse model.","method":"Conditional osteoblast-specific Slc1a5 knockout; metabolomic analysis; protein synthesis assays; differentiation assays","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type specific genetic knockout with metabolomics and multiple functional readouts establishing mechanism","pmids":["34647520"],"is_preprint":false},{"year":2019,"finding":"Slc1a5 (ASCT2) knockout mice showed mild hematopoietic defects under steady state but reduced leukemia initiation and maintenance driven by MLL-AF9 or Pten deficiency. Loss of ASCT2 disrupted leucine influx and mTOR signaling and induced apoptosis in leukemic cells. Pharmacological ASCT2 inhibition decreased human AML xenograft growth.","method":"Constitutive and inducible Slc1a5 knockout mice; MLL-AF9 and Pten-deficiency leukemia models; metabolomics; mTOR signaling assessment; xenograft models","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic knockout in two leukemia models with mechanistic metabolic analysis, multiple approaches","pmids":["31535081"],"is_preprint":false},{"year":2018,"finding":"V-9302, a competitive small molecule antagonist, selectively and potently inhibits ASCT2-mediated glutamine transport. Pharmacological ASCT2 blockade by V-9302 attenuated cancer cell growth, increased cell death, and increased oxidative stress, contributing to antitumor responses in vitro and in vivo.","method":"Competitive transport inhibition assays; glutamine uptake measurement; cancer cell proliferation/death assays; ROS measurement; xenograft tumor models","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 1 / Strong — competitive inhibition demonstrated biochemically with in vitro and in vivo validation, high-impact journal","pmids":["29334372"],"is_preprint":false},{"year":2024,"finding":"Mettl3-mediated m6A modification of Slc1a5 mRNA is recognized by Igf2bp2, which stabilizes the mRNA and promotes osteoblast senescence. Inhibition of Mettl3 reduced Slc1a5 m6A modification and expression, reducing osteoblast senescence and age-related bone loss in rats.","method":"m6A-RIP; Mettl3/Igf2bp2 overexpression/knockdown; mRNA stability assays; Cpd-564 (Mettl3 inhibitor) treatment; siRNA in vivo delivery; aged rat and OVX rat models","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — m6A-RIP establishes modification, multiple genetic approaches, single lab","pmids":["38844111"],"is_preprint":false},{"year":2023,"finding":"lncRNA SYTL5-OT4 enhances ASCT2 protein expression by inhibiting its autophagic degradation. SYTL5-OT4 interacts with ASCT2, and this interaction protects ASCT2 from autophagy-mediated degradation; ASCT2 promotes vessel co-option and tumor cell proliferation/EMT in colorectal cancer liver metastasis.","method":"RNA immunoprecipitation; co-immunoprecipitation; loss/gain-of-function experiments; autophagic flux assays; histological analysis","journal":"Drug resistance updates","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — RIP and Co-IP establish SYTL5-OT4/ASCT2 interaction with autophagic degradation assays, single lab","pmids":["37207473"],"is_preprint":false}],"current_model":"SLC1A5/ASCT2 is a sodium-dependent, electrogenic neutral amino acid antiporter that resides primarily at the plasma membrane (with a mitochondria-targeted variant) and mediates Na+-coupled obligatory exchange of glutamine, serine, asparagine, alanine, cysteine, and threonine; its transport domain undergoes rigid-body movements enabled by the ECL2a linker and HP2-loop conformational changes (established by cryo-EM and crystal structures), substrate selectivity for glutamine is conferred by two specific binding-site residues, Cys467 is critical for substrate binding and redox regulation, and N-glycosylation at Asn163/Asn212 governs plasma membrane trafficking rather than intrinsic transport activity; transcription is directly activated by MYC, ATF4, N-Myc, and ERα, repressed via miR-137 (itself silenced by MeCP2/DNMT-mediated methylation), and the protein is stabilized or degraded through interactions with DDR1, TRIM6 (ubiquitin-E3 ligase), or autophagic machinery, while functionally it supplies glutamine and serine to support TCA cycle anaplerosis, mTORC1 activation, glutathione synthesis, purine biosynthesis, and OXPHOS, making it a context-dependent but frequently essential driver of cancer cell proliferation."},"narrative":{"mechanistic_narrative":"SLC1A5 (ASCT2) is a sodium-dependent neutral amino acid antiporter that supplies glutamine and other neutral amino acids to fuel cancer cell metabolism, supporting TCA-cycle anaplerosis, mTOR signaling, redox balance, and biosynthesis [PMID:23756778, PMID:34525179, PMID:39068660]. In reconstituted proteoliposomes the purified transporter performs Na+-coupled obligatory exchange with marked kinetic asymmetry, transporting Gln, Ser, Asn, and Thr bidirectionally while moving Ala, Cys, Val, and Met inward only, operating via a random simultaneous mechanism that is electrogenic from external Na+ [PMID:23756778, PMID:25052780]. Cryo-EM and crystal structures define the transport cycle: substrate recognition involves HP2-loop conformational change, the ECL2a loop links scaffold and transport domains to permit rigid-body movement, and two substrate-binding residues confer the glutamine selectivity unique to ASCT2 within the SLC1 family [PMID:31580259, PMID:29295993]. Cys467 is critical for substrate binding and for redox/thiol modulation of activity, and cholesterol stimulates transport by increasing Vmax [PMID:29495336, PMID:31709262], while N-glycosylation at Asn163/Asn212 governs plasma-membrane trafficking rather than intrinsic transport function [PMID:25862406]. Beyond its canonical plasma-membrane role, an N-terminally extended, HIF-2α-induced variant targets mitochondria to import glutamine and drive ATP and glutathione production [PMID:31866442], and ASCT2 additionally functions as a major serine transporter feeding purine biosynthesis [PMID:39068660]. Transcription is driven by MYC/N-Myc, ATF4, and ERα [PMID:34525179, PMID:25142020, PMID:39696988, PMID:39068660] and derepressed by loss of miR-137 [PMID:28692032, PMID:29348676], while protein abundance is set by interacting partners that promote degradation (TRIM6-mediated ubiquitination, DDR1-linked lysosomal turnover) or stabilization (lncRNA SYTL5-OT4 blocking autophagic degradation) [PMID:35089546, PMID:36654781, PMID:37207473]. Genetic ablation across leukemia, colon, lung, and osteoblast models demonstrates ASCT2-dependent glutamine/serine/asparagine supply, mTOR signaling, OXPHOS, and proliferation, although in some cell lines net glutamine uptake is compensated by SNAT transporters via a GCN2-dependent stress response, making ASCT2 a context-dependent driver of growth [PMID:27129276, PMID:29326164, PMID:34525179, PMID:34647520, PMID:31535081]. ASCT2 also serves as a receptor for several retroviruses through a hypervariable ECL2 segment whose N-glycans restrict viral entry [PMID:12584318, PMID:11350958].","teleology":[{"year":2001,"claim":"Resolved which structural elements of ASCT2 are required for amino acid transport versus retroviral receptor function, separating its two activities.","evidence":"Initiation-codon mutagenesis and cell-free translation generating N-terminal truncation isoforms tested in transport and infection assays","pmids":["11350958"],"confidence":"High","gaps":["Did not define the full transport mechanism","Physiological role of leaky-scanning isoforms unclear"]},{"year":2003,"claim":"Mapped the determinant of ASCT2 retroviral receptor function and showed N-glycans on ECL2 restrict viral entry.","evidence":"Human/mouse chimeras, glycosylation-site mutagenesis, and tunicamycin treatment with viral susceptibility readouts","pmids":["12584318"],"confidence":"High","gaps":["Did not address endogenous transport consequences of these residues"]},{"year":2004,"claim":"Showed ASCT2 expression is feedback-regulated by its own substrate, linking glutamine availability to transporter abundance.","evidence":"ASCT2 promoter luciferase reporter plus Western blot under glutamine deprivation/repletion in hepatoma cells","pmids":["15175006"],"confidence":"Medium","gaps":["Transcription factor mediating glutamine sensing not identified","Single cell line"]},{"year":2006,"claim":"Established that substrate supply drives ASCT2 relocation to the plasma membrane, coupling astrocytic glutamate metabolism to transporter surface expression.","evidence":"GS siRNA knockdown with immunofluorescence and transport assays in human fetal astrocytes","pmids":["16516348"],"confidence":"Medium","gaps":["Trafficking machinery undefined","Single lab"]},{"year":2013,"claim":"Provided the first quantitative mechanism of human ASCT2 as an asymmetric Na+-dependent obligatory antiporter with distinct substrate directionality.","evidence":"Recombinant protein reconstituted in proteoliposomes with radiolabeled transport kinetics","pmids":["23756778"],"confidence":"High","gaps":["Atomic structure not yet resolved","Functional role of externally exposed cysteine inferred not proven"]},{"year":2014,"claim":"Defined the kinetic mechanism, electrogenicity, oligomeric state, and a scaffold partner of ASCT2.","evidence":"Pseudo-bi-substrate kinetics, cross-linking, valinomycin membrane-potential assays, and PDZK1 co-IP","pmids":["25052780"],"confidence":"High","gaps":["Physiological significance of PDZK1 interaction not established"]},{"year":2014,"claim":"Identified ATF4 and N-Myc as direct transcriptional activators coupling oncogenic signaling to ASCT2 expression.","evidence":"ChIP and luciferase reporter assays with depletion and proliferation readouts in neuroblastoma","pmids":["25142020"],"confidence":"Medium","gaps":["Single lab","Cooperativity mechanism between ATF4 and N-Myc not detailed"]},{"year":2015,"claim":"Separated the role of N-glycosylation in membrane trafficking from intrinsic transport activity.","evidence":"N163/212Q mutagenesis with biotinylation, endocytosis, stability, and reconstituted transport assays","pmids":["25862406"],"confidence":"High","gaps":["Trafficking/endocytic machinery downstream of glycan loss undefined"]},{"year":2016,"claim":"Tested whether ASCT2 is the obligate glutamine transporter and revealed compensatory redundancy via a GCN2-driven stress response.","evidence":"CRISPR/TALEN ASCT2 deletion with GCN2 epistasis and amino acid uptake assays","pmids":["27129276"],"confidence":"High","gaps":["Context-dependence across cell types not fully mapped","Did not test in vivo tumors"]},{"year":2016,"claim":"Linked ASCT2 to EGFR in a complex governing glutamine-dependent redox protection.","evidence":"Co-IP, EGFR endocytosis, glutamine uptake, glutathione, and apoptosis assays in HNSCC","pmids":["27450723"],"confidence":"Medium","gaps":["Direct vs indirect EGFR-ASCT2 interaction not resolved","Single lab"]},{"year":2017,"claim":"Established an epigenetic-microRNA axis (MeCP2/DNMT-miR-137) controlling ASCT2 expression in cancer.","evidence":"Promoter methylation analysis, ChIP, miR-137 modulation, and ASCT2 3'UTR rescue","pmids":["28692032"],"confidence":"Medium","gaps":["Single lab","Generality across tumor types unverified"]},{"year":2018,"claim":"Delivered atomic structures defining the ASCT2 transport cycle and the structural basis of glutamine selectivity and inhibitor binding.","evidence":"Cryo-EM of human ASCT2 and crystal structures of a prokaryotic homologue with substrate-binding mutagenesis","pmids":["31580259","29295993"],"confidence":"High","gaps":["Conformational dynamics in lipid bilayers not directly captured","Cholesterol site functional role addressed separately"]},{"year":2018,"claim":"Identified Cys467 as a substrate-binding residue mediating redox modulation of ASCT2 activity.","evidence":"Systematic Cys-to-Ala mutagenesis with transport assays in proteoliposomes","pmids":["29495336"],"confidence":"High","gaps":["Physiological redox signals acting on Cys467 in cells not defined"]},{"year":2018,"claim":"Demonstrated ASCT2 KO reduces glutamine import and tumor growth independent of LAT1 and mTORC1 in certain contexts, refining its role.","evidence":"CRISPR-Cas9 KO in colon and lung lines with uptake, signaling, and xenograft assays","pmids":["29326164"],"confidence":"High","gaps":["Mechanism of growth dependence without mTORC1 change unexplained"]},{"year":2018,"claim":"Validated ASCT2 as a druggable target with a competitive small-molecule antagonist showing antitumor activity.","evidence":"V-9302 competitive inhibition, glutamine uptake, ROS, and xenograft assays","pmids":["29334372"],"confidence":"High","gaps":["Selectivity later debated; on-target specificity not addressed here"]},{"year":2018,"claim":"Connected ASCT2 to ferroptosis regulation via miR-137 targeting.","evidence":"miR-137 modulation, 3'UTR luciferase, glutamine uptake, MDA, and ferroptosis-inducer assays in melanoma","pmids":["29348676"],"confidence":"Medium","gaps":["Single lab","Quantitative contribution to ferroptosis vs other regulators unclear"]},{"year":2019,"claim":"Discovered a mitochondria-targeted ASCT2 variant supplying intramitochondrial glutamine for ATP and glutathione, regulated by hypoxia.","evidence":"Mitochondrial fractionation, imaging, siRNA, metabolic assays, HIF-2α ChIP, and xenografts","pmids":["31866442"],"confidence":"High","gaps":["Mechanism of dual targeting (PM vs mitochondria) not fully defined"]},{"year":2019,"claim":"Established MYC as a direct activator of SLC1A5 coupling it to mTORC1 and fatty acid oxidation in vivo.","evidence":"Myc+/- mouse gene expression, glutamine uptake, mTORC1 and Cpt1a analyses","pmids":["30909319"],"confidence":"Medium","gaps":["Direct MYC promoter binding inferred from prior work","Single lab"]},{"year":2019,"claim":"Demonstrated in vivo that ASCT2 supports leukemia initiation/maintenance via leucine influx and mTOR signaling.","evidence":"Constitutive/inducible Slc1a5 KO mice in MLL-AF9 and Pten leukemia models with metabolomics and xenografts","pmids":["31535081"],"confidence":"High","gaps":["Mechanism linking ASCT2 to leucine influx not fully resolved"]},{"year":2021,"claim":"Defined the physiological requirement for ASCT2 in osteoblast differentiation via glutamine/asparagine supply.","evidence":"Osteoblast-specific Slc1a5 KO with metabolomics and protein-synthesis/differentiation assays","pmids":["34647520"],"confidence":"High","gaps":["Tissue-specificity of dependence not generalized"]},{"year":2021,"claim":"Enabled structure-guided design of stereospecific ASCT2 inhibitors and revealed multiple pharmacological conformations.","evidence":"Cryo-EM, molecular dynamics, and electrophysiology transport assays","pmids":["34507995"],"confidence":"High","gaps":["In vivo efficacy of designed inhibitors not assessed here"]},{"year":2022,"claim":"Identified TRIM6 as an E3 ligase degrading ASCT2 to restrain glutaminolysis and ferroptosis.","evidence":"Co-IP, ubiquitination assays, glutamine uptake, ferroptosis, and xenograft models in lung cancer","pmids":["36654781"],"confidence":"Medium","gaps":["Single lab","Ubiquitination site on ASCT2 not mapped"]},{"year":2022,"claim":"Identified DDR1 as a regulator of ASCT2 stability via lysosomal degradation feeding mTORC1.","evidence":"Co-IP, CHX stability, lysosomal-inhibitor rescue, and xenograft assays","pmids":["35089546"],"confidence":"Medium","gaps":["Single lab","Mechanism of DDR1-directed lysosomal routing unclear"]},{"year":2022,"claim":"Placed STAT3->MYC->SLC1A5 as a transcriptional axis sustaining OXPHOS in leukemia stem cells.","evidence":"Genetic inhibition of STAT3/MYC/SLC1A5 with metabolomics and OXPHOS measurement in primary AML","pmids":["34525179"],"confidence":"High","gaps":["Direct STAT3 occupancy of MYC locus not detailed in this entry"]},{"year":2022,"claim":"Revealed non-transport scaffolding roles of ASCT2 in inflammatory signaling through NLRP3 and pro-IL-1α binding.","evidence":"Co-IP, astrocytic conditional KO/MPTP and hepatic stellate cell senescence models","pmids":["36873178","36176909"],"confidence":"Medium","gaps":["Single labs","Direct vs transport-dependent contributions to phenotypes not fully separated"]},{"year":2023,"claim":"Showed CAIX physically partners with SLC1A5 to coordinate redox homeostasis via the GSH/GPX4 axis.","evidence":"Co-IP, glutamine uptake, GSH/lipid peroxidation, and in vivo tumor models","pmids":["37348875"],"confidence":"Medium","gaps":["Single lab","Structural basis of CAIX-SLC1A5 interaction unknown"]},{"year":2023,"claim":"Identified lncRNA SYTL5-OT4 as a stabilizer of ASCT2 protein by blocking its autophagic degradation in metastasis.","evidence":"RIP, Co-IP, autophagic flux, and loss/gain-of-function in colorectal liver metastasis","pmids":["37207473"],"confidence":"Medium","gaps":["Single lab","Mechanism of autophagy targeting of ASCT2 unresolved"]},{"year":2024,"claim":"Established ASCT2 as a major serine transporter feeding purine biosynthesis and identified ERα as a direct transcriptional activator.","evidence":"ASCT2 KO/KD with serine uptake, glutamine/serine competition, purine metabolomics, and ERα ChIP","pmids":["39068660"],"confidence":"High","gaps":["Relative physiological balance of serine vs glutamine transport in vivo unclear"]},{"year":2024,"claim":"Added ATF4 as a direct activator of SLC1A5 linking it to glucose and glycolytic enzyme regulation in colorectal cancer.","evidence":"Luciferase reporter, ChIP, and SLC1A5 knockdown metabolic assays","pmids":["39696988"],"confidence":"Medium","gaps":["Single lab","Mechanism linking ASCT2 to HK2/PKM2 expression unclear"]},{"year":2024,"claim":"Showed m6A modification stabilizes Slc1a5 mRNA to drive osteoblast senescence and bone loss.","evidence":"m6A-RIP, Mettl3/Igf2bp2 modulation, mRNA stability, inhibitor and aged/OVX rat models","pmids":["38844111"],"confidence":"Medium","gaps":["Single lab","m6A sites on Slc1a5 not precisely mapped"]},{"year":null,"claim":"How transport-dependent and transport-independent (scaffolding) functions of ASCT2 are integrated, and what determines its context-dependent essentiality across tissues, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model reconciling redundant vs essential glutamine uptake across cell types","Mechanism of dual PM/mitochondrial targeting undefined","Transport-independent inflammatory roles mechanistically unexplained"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[3,4,18,27,30]},{"term_id":"GO:0140104","term_label":"molecular carrier activity","supporting_discovery_ids":[3,7,27]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[9,10]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[6,25]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[7]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[25]}],"pathway":[{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[3,4,27]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[7,19,27,28]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[13,24]}],"complexes":[],"partners":["PDZK1","EGFR","DDR1","TRIM6","NLRP3","IL1A","CA9"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q15758","full_name":"Neutral amino acid transporter B(0)","aliases":["Baboon M7 virus receptor","RD114/simian type D retrovirus receptor","Sodium-dependent neutral amino acid transporter type 2","Solute carrier family 1 member 5"],"length_aa":541,"mass_kda":56.6,"function":"Sodium-coupled antiporter of neutral amino acids. In a tri-substrate transport cycle, exchanges neutral amino acids between the extracellular and intracellular compartments, coupled to the inward cotransport of at least one sodium ion (PubMed:17094966, PubMed:23756778, PubMed:26492990, PubMed:29872227, PubMed:34741534, PubMed:8702519, PubMed:39095408, PubMed:27272177). The preferred substrate is the essential amino acid L-glutamine, a precursor for biosynthesis of proteins, nucleotides and amine sugars as well as an alternative fuel for mitochondrial oxidative phosphorylation. Exchanges L-glutamine with other neutral amino acids such as L-serine, L-threonine and L-asparagine in a bidirectional way. Provides L-glutamine to proliferating stem and activated cells driving the metabolic switch toward cell differentiation (PubMed:23756778, PubMed:24953180). The transport cycle is usually pH-independent, with the exception of L-glutamate. Transports extracellular L-glutamate coupled to the cotransport of one proton and one sodium ion in exchange for intracellular L-glutamine counter-ion. May provide for L-glutamate uptake in glial cells regulating glutamine/glutamate cycle in the nervous system (PubMed:32733894). Can transport D-amino acids. Mediates D-serine release from the retinal glia potentially affecting NMDA receptor function in retinal neurons (PubMed:17094966). Displays sodium- and amino acid-dependent but uncoupled channel-like anion conductance with a preference SCN(-) >> NO3(-) > I(-) > Cl(-) (By similarity). Through binding of the fusogenic protein syncytin-1/ERVW-1 may mediate trophoblasts syncytialization, the spontaneous fusion of their plasma membranes, an essential process in placental development (PubMed:10708449, PubMed:23492904, PubMed:38671230) (Microbial infection) Acts as a cell surface receptor for Feline endogenous virus RD114 (Microbial infection) Acts as a cell surface receptor for Baboon M7 endogenous virus (Microbial infection) Acts as a cell surface receptor for type D simian retroviruses","subcellular_location":"Cell membrane; Melanosome","url":"https://www.uniprot.org/uniprotkb/Q15758/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SLC1A5","classification":"Not Classified","n_dependent_lines":145,"n_total_lines":1208,"dependency_fraction":0.12003311258278146},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000105281","cell_line_id":"CID001318","localizations":[{"compartment":"membrane","grade":3},{"compartment":"vesicles","grade":3}],"interactors":[{"gene":"RAB11A","stoichiometry":4.0},{"gene":"CALD1","stoichiometry":0.2},{"gene":"CANX","stoichiometry":0.2},{"gene":"CAPZB","stoichiometry":0.2},{"gene":"GNB1","stoichiometry":0.2},{"gene":"STX4","stoichiometry":0.2},{"gene":"PYCR2","stoichiometry":0.2},{"gene":"SLC1A4","stoichiometry":0.2},{"gene":"SRP9","stoichiometry":0.2},{"gene":"VAMP3","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001318","total_profiled":1310},"omim":[{"mim_id":"600229","title":"SOLUTE CARRIER FAMILY 1 (GLUTAMATE/NEUTRAL AMINO ACID TRANSPORTER), MEMBER 4; SLC1A4","url":"https://www.omim.org/entry/600229"},{"mim_id":"109190","title":"SOLUTE CARRIER FAMILY 1 (NEUTRAL AMINO ACID TRANSPORTER), MEMBER 5; SLC1A5","url":"https://www.omim.org/entry/109190"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Centriolar satellite","reliability":"Additional"},{"location":"Basal body","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/SLC1A5"},"hgnc":{"alias_symbol":["AAAT","ASCT2"],"prev_symbol":["RDRC","M7V1"]},"alphafold":{"accession":"Q15758","domains":[{"cath_id":"1.10.3860.10","chopping":"54-493","consensus_level":"medium","plddt":88.3852,"start":54,"end":493}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15758","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q15758-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q15758-F1-predicted_aligned_error_v6.png","plddt_mean":78.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SLC1A5","jax_strain_url":"https://www.jax.org/strain/search?query=SLC1A5"},"sequence":{"accession":"Q15758","fasta_url":"https://rest.uniprot.org/uniprotkb/Q15758.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q15758/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15758"}},"corpus_meta":[{"pmid":"15916903","id":"PMC_15916903","title":"Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime?","date":"2005","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/15916903","citation_count":594,"is_preprint":false},{"pmid":"26455325","id":"PMC_26455325","title":"ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26455325","citation_count":494,"is_preprint":false},{"pmid":"15607976","id":"PMC_15607976","title":"Two RNAi complexes, RITS and RDRC, physically interact and localize to noncoding centromeric RNAs.","date":"2004","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/15607976","citation_count":451,"is_preprint":false},{"pmid":"29334372","id":"PMC_29334372","title":"Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models.","date":"2018","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29334372","citation_count":416,"is_preprint":false},{"pmid":"29348676","id":"PMC_29348676","title":"miR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma.","date":"2018","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/29348676","citation_count":396,"is_preprint":false},{"pmid":"31866442","id":"PMC_31866442","title":"A Variant of SLC1A5 Is a Mitochondrial Glutamine Transporter for Metabolic Reprogramming in Cancer Cells.","date":"2019","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/31866442","citation_count":369,"is_preprint":false},{"pmid":"23213057","id":"PMC_23213057","title":"SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival.","date":"2012","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/23213057","citation_count":297,"is_preprint":false},{"pmid":"25693838","id":"PMC_25693838","title":"Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development.","date":"2015","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25693838","citation_count":292,"is_preprint":false},{"pmid":"30234109","id":"PMC_30234109","title":"The Human SLC1A5 (ASCT2) Amino Acid Transporter: From Function to Structure and Role in Cell Biology.","date":"2018","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/30234109","citation_count":213,"is_preprint":false},{"pmid":"27129276","id":"PMC_27129276","title":"Deletion of Amino Acid Transporter ASCT2 (SLC1A5) Reveals an Essential Role for Transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to Sustain Glutaminolysis in Cancer Cells.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27129276","citation_count":211,"is_preprint":false},{"pmid":"29326164","id":"PMC_29326164","title":"The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29326164","citation_count":147,"is_preprint":false},{"pmid":"25821004","id":"PMC_25821004","title":"Targeting SLC1a5-mediated glutamine dependence in non-small cell lung cancer.","date":"2015","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25821004","citation_count":143,"is_preprint":false},{"pmid":"25142020","id":"PMC_25142020","title":"ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation.","date":"2014","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25142020","citation_count":137,"is_preprint":false},{"pmid":"33953707","id":"PMC_33953707","title":"Targeting SLC1A5 and SLC3A2/SLC7A5 as a Potential Strategy to Strengthen Anti-Tumor Immunity in the Tumor Microenvironment.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33953707","citation_count":135,"is_preprint":false},{"pmid":"30025811","id":"PMC_30025811","title":"The role of ASCT2 in cancer: A review.","date":"2018","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30025811","citation_count":135,"is_preprint":false},{"pmid":"34525179","id":"PMC_34525179","title":"The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/34525179","citation_count":119,"is_preprint":false},{"pmid":"31819178","id":"PMC_31819178","title":"ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma.","date":"2019","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31819178","citation_count":114,"is_preprint":false},{"pmid":"12584318","id":"PMC_12584318","title":"N-linked glycosylation and sequence changes in a critical negative control region of the ASCT1 and ASCT2 neutral amino acid transporters determine their retroviral receptor functions.","date":"2003","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/12584318","citation_count":91,"is_preprint":false},{"pmid":"16411991","id":"PMC_16411991","title":"Altered placental syncytin and its receptor ASCT2 expression in placental development and pre-eclampsia.","date":"2006","source":"BJOG : an international journal of obstetrics and gynaecology","url":"https://pubmed.ncbi.nlm.nih.gov/16411991","citation_count":88,"is_preprint":false},{"pmid":"12401089","id":"PMC_12401089","title":"Cyclic trinuclear and chain of cyclic trinuclear copper(II) complexes containing a pyramidal Cu(3)O(H) core. Crystal structures and magnetic properties of [Cu(3)(mu(3)-OH)(aaat)(3)(H(2)O)(3)](NO(3))(2).H(2)O [aaat = 3-acetylamino-5-amino-1,2,4-triazolate] and ([Cu(3)(mu(3)-OH)(aat)(3)(mu(3)-SO(4))].6H(2)O)(n) [aat = 3-acetylamino-1,2,4-triazolate]: new cases of spin-frustrated systems.","date":"2002","source":"Inorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12401089","citation_count":85,"is_preprint":false},{"pmid":"30635397","id":"PMC_30635397","title":"Ablation of the ASCT2 (SLC1A5) gene encoding a neutral amino acid transporter reveals transporter plasticity and redundancy in cancer cells.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30635397","citation_count":84,"is_preprint":false},{"pmid":"31535081","id":"PMC_31535081","title":"Critical role of ASCT2-mediated amino acid metabolism in promoting leukaemia development and progression.","date":"2019","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/31535081","citation_count":78,"is_preprint":false},{"pmid":"32438035","id":"PMC_32438035","title":"Target the human Alanine/Serine/Cysteine Transporter 2(ASCT2): Achievement and Future for Novel Cancer Therapy.","date":"2020","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/32438035","citation_count":78,"is_preprint":false},{"pmid":"25337245","id":"PMC_25337245","title":"Upregulated SLC1A5 promotes cell growth and survival in colorectal cancer.","date":"2014","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25337245","citation_count":74,"is_preprint":false},{"pmid":"31409775","id":"PMC_31409775","title":"Long noncoding RNA ABHD11-AS1 functions as a competing endogenous RNA to regulate papillary thyroid cancer progression by miR-199a-5p/SLC1A5 axis.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31409775","citation_count":74,"is_preprint":false},{"pmid":"36566214","id":"PMC_36566214","title":"SLC1A5 enhances malignant phenotypes through modulating ferroptosis status and immune microenvironment in glioma.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36566214","citation_count":73,"is_preprint":false},{"pmid":"38190923","id":"PMC_38190923","title":"Quercetin induces ferroptosis in gastric cancer cells by targeting SLC1A5 and regulating the p-Camk2/p-DRP1 and NRF2/GPX4 Axes.","date":"2024","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38190923","citation_count":71,"is_preprint":false},{"pmid":"29295993","id":"PMC_29295993","title":"Structural characterisation reveals insights into substrate recognition by the glutamine transporter ASCT2/SLC1A5.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29295993","citation_count":66,"is_preprint":false},{"pmid":"28759021","id":"PMC_28759021","title":"ASCT2 regulates glutamine uptake and cell growth in endometrial carcinoma.","date":"2017","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/28759021","citation_count":65,"is_preprint":false},{"pmid":"31580259","id":"PMC_31580259","title":"Cryo-EM structures of the human glutamine transporter SLC1A5 (ASCT2) in the outward-facing conformation.","date":"2019","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/31580259","citation_count":64,"is_preprint":false},{"pmid":"12926082","id":"PMC_12926082","title":"Expression of neutral amino acid transporter ASCT2 in human prostate.","date":"2003","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12926082","citation_count":63,"is_preprint":false},{"pmid":"28749408","id":"PMC_28749408","title":"Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28749408","citation_count":62,"is_preprint":false},{"pmid":"25862406","id":"PMC_25862406","title":"N-linked glycosylation of human SLC1A5 (ASCT2) transporter is critical for trafficking to membrane.","date":"2015","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/25862406","citation_count":62,"is_preprint":false},{"pmid":"29435734","id":"PMC_29435734","title":"Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth.","date":"2018","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29435734","citation_count":60,"is_preprint":false},{"pmid":"36176909","id":"PMC_36176909","title":"Inhibition of ASCT2 induces hepatic stellate cell senescence with modified proinflammatory secretome through an IL-1α/NF-κB feedback pathway to inhibit liver fibrosis.","date":"2022","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/36176909","citation_count":58,"is_preprint":false},{"pmid":"30909319","id":"PMC_30909319","title":"SLC1A5 glutamine transporter is a target of MYC and mediates reduced mTORC1 signaling and increased fatty acid oxidation in long-lived Myc hypomorphic mice.","date":"2019","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/30909319","citation_count":58,"is_preprint":false},{"pmid":"26444490","id":"PMC_26444490","title":"Ligand Discovery for the Alanine-Serine-Cysteine Transporter (ASCT2, SLC1A5) from Homology Modeling and Virtual Screening.","date":"2015","source":"PLoS computational biology","url":"https://pubmed.ncbi.nlm.nih.gov/26444490","citation_count":57,"is_preprint":false},{"pmid":"23756778","id":"PMC_23756778","title":"Large scale production of the active human ASCT2 (SLC1A5) transporter in Pichia pastoris--functional and kinetic asymmetry revealed in proteoliposomes.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23756778","citation_count":55,"is_preprint":false},{"pmid":"25052780","id":"PMC_25052780","title":"Transport mechanism and regulatory properties of the human amino acid transporter ASCT2 (SLC1A5).","date":"2014","source":"Amino acids","url":"https://pubmed.ncbi.nlm.nih.gov/25052780","citation_count":55,"is_preprint":false},{"pmid":"25297701","id":"PMC_25297701","title":"Expression of amino acid transporters (LAT1, ASCT2 and xCT) as clinical significance in hepatocellular carcinoma.","date":"2014","source":"Hepatology research : the official journal of the Japan Society of Hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/25297701","citation_count":54,"is_preprint":false},{"pmid":"27450723","id":"PMC_27450723","title":"ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.","date":"2016","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/27450723","citation_count":52,"is_preprint":false},{"pmid":"28692032","id":"PMC_28692032","title":"Epigenetic silencing of microRNA-137 enhances ASCT2 expression and tumor glutamine metabolism.","date":"2017","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/28692032","citation_count":50,"is_preprint":false},{"pmid":"12175968","id":"PMC_12175968","title":"Changes in expression and function of syncytin and its receptor, amino acid transport system B(0) (ASCT2), in human placental choriocarcinoma BeWo cells during syncytialization.","date":"2002","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/12175968","citation_count":50,"is_preprint":false},{"pmid":"34507995","id":"PMC_34507995","title":"Rational design of ASCT2 inhibitors using an integrated experimental-computational approach.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/34507995","citation_count":49,"is_preprint":false},{"pmid":"33429909","id":"PMC_33429909","title":"ASCT2 and LAT1 Contribution to the Hallmarks of Cancer: From a Molecular Perspective to Clinical Translation.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33429909","citation_count":48,"is_preprint":false},{"pmid":"10559472","id":"PMC_10559472","title":"Regulation of signal transducers and activators of transcription (STATs) by effectors of adipogenesis: coordinate regulation of STATs 1, 5A, and 5B with peroxisome proliferator-activated receptor-gamma and C/AAAT enhancer binding protein-alpha.","date":"1999","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/10559472","citation_count":47,"is_preprint":false},{"pmid":"34647520","id":"PMC_34647520","title":"SLC1A5 provides glutamine and asparagine necessary for bone development in mice.","date":"2021","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/34647520","citation_count":46,"is_preprint":false},{"pmid":"29363109","id":"PMC_29363109","title":"Inhibition of SLC1A5 sensitizes colorectal cancer to cetuximab.","date":"2018","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29363109","citation_count":46,"is_preprint":false},{"pmid":"26936531","id":"PMC_26936531","title":"Clinicopathological significance of LAT1 and ASCT2 in patients with surgically resected esophageal squamous cell carcinoma.","date":"2016","source":"Journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26936531","citation_count":45,"is_preprint":false},{"pmid":"29100325","id":"PMC_29100325","title":"Effects of targeting SLC1A5 on inhibiting gastric cancer growth and tumor development in vitro and in vivo.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29100325","citation_count":43,"is_preprint":false},{"pmid":"25971659","id":"PMC_25971659","title":"Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer.","date":"2016","source":"Molecular imaging and biology","url":"https://pubmed.ncbi.nlm.nih.gov/25971659","citation_count":43,"is_preprint":false},{"pmid":"26278491","id":"PMC_26278491","title":"[(14)C]Fluciclovine (alias anti-[(14)C]FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells.","date":"2015","source":"Nuclear medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/26278491","citation_count":42,"is_preprint":false},{"pmid":"15175006","id":"PMC_15175006","title":"Glutamine availability up-regulates expression of the amino acid transporter protein ASCT2 in HepG2 cells and stimulates the ASCT2 promoter.","date":"2004","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/15175006","citation_count":41,"is_preprint":false},{"pmid":"30029480","id":"PMC_30029480","title":"Targeted Suppression and Knockout of ASCT2 or LAT1 in Epithelial and Mesenchymal Human Liver Cancer Cells Fail to Inhibit Growth.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30029480","citation_count":38,"is_preprint":false},{"pmid":"28553292","id":"PMC_28553292","title":"ASCT2 (SLC1A5)-Deficient Mice Have Normal B-Cell Development, Proliferation, and Antibody Production.","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28553292","citation_count":37,"is_preprint":false},{"pmid":"30071532","id":"PMC_30071532","title":"SLC1A5 Silencing Inhibits Esophageal Cancer Growth via Cell Cycle Arrest and Apoptosis.","date":"2018","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30071532","citation_count":37,"is_preprint":false},{"pmid":"32658600","id":"PMC_32658600","title":"Circular RNA circ-LDLRAD3 serves as an oncogene to promote non-small cell lung cancer progression by upregulating SLC1A5 through sponging miR-137.","date":"2020","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/32658600","citation_count":37,"is_preprint":false},{"pmid":"35237783","id":"PMC_35237783","title":"Targeting ASCT2-mediated glutamine metabolism inhibits proliferation and promotes apoptosis of pancreatic cancer cells.","date":"2022","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/35237783","citation_count":36,"is_preprint":false},{"pmid":"35320491","id":"PMC_35320491","title":"A novel miR-338-3p/SLC1A5 axis reprograms retinal pigment epithelium to increases its resistance to high glucose-induced cell ferroptosis.","date":"2022","source":"Journal of molecular histology","url":"https://pubmed.ncbi.nlm.nih.gov/35320491","citation_count":36,"is_preprint":false},{"pmid":"33464409","id":"PMC_33464409","title":"The role of the glutamine transporter ASCT2 in antineoplastic therapy.","date":"2021","source":"Cancer chemotherapy and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33464409","citation_count":35,"is_preprint":false},{"pmid":"26024742","id":"PMC_26024742","title":"Expression of Amino Acid Transporters (LAT1 and ASCT2) in Patients with Stage III/IV Laryngeal Squamous Cell Carcinoma.","date":"2015","source":"Pathology oncology research : POR","url":"https://pubmed.ncbi.nlm.nih.gov/26024742","citation_count":35,"is_preprint":false},{"pmid":"31709772","id":"PMC_31709772","title":"Anti-tumor effects of an antagonistic mAb against the ASCT2 amino acid transporter on KRAS-mutated human colorectal cancer cells.","date":"2019","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31709772","citation_count":35,"is_preprint":false},{"pmid":"27865832","id":"PMC_27865832","title":"Establishment of monoclonal antibodies against cell surface domains of ASCT2/SLC1A5 and their inhibition of glutamine-dependent tumor cell growth.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27865832","citation_count":34,"is_preprint":false},{"pmid":"34530825","id":"PMC_34530825","title":"Circ-SFMBT2 drives the malignant phenotypes of esophageal cancer by the miR-107-dependent regulation of SLC1A5.","date":"2021","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/34530825","citation_count":34,"is_preprint":false},{"pmid":"30668314","id":"PMC_30668314","title":"Topotecan induces apoptosis via ASCT2 mediated oxidative stress in gastric cancer.","date":"2018","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30668314","citation_count":33,"is_preprint":false},{"pmid":"35419359","id":"PMC_35419359","title":"SLC1A5 Prefers to Play as an Accomplice Rather Than an Opponent in Pancreatic Adenocarcinoma.","date":"2022","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/35419359","citation_count":31,"is_preprint":false},{"pmid":"34269129","id":"PMC_34269129","title":"ASCT1 and ASCT2: Brother and Sister?","date":"2021","source":"SLAS discovery : advancing life sciences R & D","url":"https://pubmed.ncbi.nlm.nih.gov/34269129","citation_count":30,"is_preprint":false},{"pmid":"33713737","id":"PMC_33713737","title":"Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.","date":"2021","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/33713737","citation_count":30,"is_preprint":false},{"pmid":"36873178","id":"PMC_36873178","title":"Impeding the combination of astrocytic ASCT2 and NLRP3 by talniflumate alleviates neuroinflammation in experimental models of Parkinson's disease.","date":"2022","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/36873178","citation_count":29,"is_preprint":false},{"pmid":"35089546","id":"PMC_35089546","title":"Discoidin domain receptor 1 promotes hepatocellular carcinoma progression through modulation of SLC1A5 and the mTORC1 signaling pathway.","date":"2022","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/35089546","citation_count":28,"is_preprint":false},{"pmid":"38217503","id":"PMC_38217503","title":"Discovery of Novel Aminobutanoic Acid-Based ASCT2 Inhibitors for the Treatment of Non-Small-Cell Lung Cancer.","date":"2024","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38217503","citation_count":28,"is_preprint":false},{"pmid":"11350958","id":"PMC_11350958","title":"Truncated forms of the dual function human ASCT2 neutral amino acid transporter/retroviral receptor are translationally initiated at multiple alternative CUG and GUG codons.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11350958","citation_count":28,"is_preprint":false},{"pmid":"35680143","id":"PMC_35680143","title":"Inspiratory hyperoxia suppresses lung cancer metastasis through a MYC/SLC1A5-dependent metabolic pathway.","date":"2022","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/35680143","citation_count":27,"is_preprint":false},{"pmid":"36262284","id":"PMC_36262284","title":"Glutamine Transporter SLC1A5 Regulates Ionizing Radiation-Derived Oxidative Damage and Ferroptosis.","date":"2022","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/36262284","citation_count":26,"is_preprint":false},{"pmid":"36273140","id":"PMC_36273140","title":"circ_0025033 promotes ovarian cancer development via regulating the hsa_miR-370-3p/SLC1A5 axis.","date":"2022","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/36273140","citation_count":26,"is_preprint":false},{"pmid":"36654781","id":"PMC_36654781","title":"TRIM6 Reduces Ferroptosis and Chemosensitivity by Targeting SLC1A5 in Lung Cancer.","date":"2023","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/36654781","citation_count":25,"is_preprint":false},{"pmid":"29495336","id":"PMC_29495336","title":"Cys Site-Directed Mutagenesis of the Human SLC1A5 (ASCT2) Transporter: Structure/Function Relationships and Crucial Role of Cys467 for Redox Sensing and Glutamine Transport.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29495336","citation_count":24,"is_preprint":false},{"pmid":"37459644","id":"PMC_37459644","title":"Targeting Pulmonary Fibrosis by SLC1A5-Dependent Glutamine Transport Blockade.","date":"2023","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/37459644","citation_count":23,"is_preprint":false},{"pmid":"39068660","id":"PMC_39068660","title":"ASCT2 is a major contributor to serine uptake in cancer cells.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/39068660","citation_count":23,"is_preprint":false},{"pmid":"37348875","id":"PMC_37348875","title":"A Carbonic Anhydrase IX/SLC1A5 Axis Regulates Glutamine Metabolism Dependent Ferroptosis in Hypoxic Tumor Cells.","date":"2023","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/37348875","citation_count":23,"is_preprint":false},{"pmid":"31150647","id":"PMC_31150647","title":"Metformin inhibits PPARδ agonist-mediated tumor growth by reducing Glut1 and SLC1A5 expressions of cancer cells.","date":"2019","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31150647","citation_count":23,"is_preprint":false},{"pmid":"16516348","id":"PMC_16516348","title":"High-affinity glutamate transporter GLAST/EAAT1 regulates cell surface expression of glutamine/neutral amino acid transporter ASCT2 in human fetal astrocytes.","date":"2006","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/16516348","citation_count":21,"is_preprint":false},{"pmid":"32355746","id":"PMC_32355746","title":"Enhanced glutamine utilization mediated by SLC1A5 and GPT2 is an essential metabolic feature of colorectal signet ring cell carcinoma with therapeutic potential.","date":"2020","source":"Annals of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32355746","citation_count":21,"is_preprint":false},{"pmid":"34282517","id":"PMC_34282517","title":"SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer.","date":"2021","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/34282517","citation_count":20,"is_preprint":false},{"pmid":"37772564","id":"PMC_37772564","title":"miR-122-5p Restrains Pancreatic Cancer Cell Growth and Causes Apoptosis by Negatively Regulating ASCT2.","date":"2023","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/37772564","citation_count":20,"is_preprint":false},{"pmid":"34132956","id":"PMC_34132956","title":"Circ_0072995 Promotes Ovarian Cancer Progression Through Regulating miR-122-5p/SLC1A5 Axis.","date":"2021","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34132956","citation_count":20,"is_preprint":false},{"pmid":"37478011","id":"PMC_37478011","title":"QUAS-R: An SLC1A5-mediated glutamine uptake assay with single-cell resolution reveals metabolic heterogeneity with immune populations.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37478011","citation_count":19,"is_preprint":false},{"pmid":"37894450","id":"PMC_37894450","title":"A Novel ASCT2 Inhibitor, C118P, Blocks Glutamine Transport and Exhibits Antitumour Efficacy in Breast Cancer.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/37894450","citation_count":18,"is_preprint":false},{"pmid":"35418865","id":"PMC_35418865","title":"Ag120-Mediated Inhibition of ASCT2-Dependent Glutamine Transport has an Anti-Tumor Effect on Colorectal Cancer Cells.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35418865","citation_count":18,"is_preprint":false},{"pmid":"31709262","id":"PMC_31709262","title":"Interaction of Cholesterol With the Human SLC1A5 (ASCT2): Insights Into Structure/Function Relationships.","date":"2019","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/31709262","citation_count":18,"is_preprint":false},{"pmid":"35487063","id":"PMC_35487063","title":"Targeting of the glutamine transporter SLC1A5 induces cellular senescence in clear cell renal cell carcinoma.","date":"2022","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/35487063","citation_count":16,"is_preprint":false},{"pmid":"38844111","id":"PMC_38844111","title":"Inhibition of Mettl3 ameliorates osteoblastic senescence by mitigating m6A modifications on Slc1a5 via Igf2bp2-dependent mechanisms.","date":"2024","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/38844111","citation_count":16,"is_preprint":false},{"pmid":"37566748","id":"PMC_37566748","title":"SLC1A5 is a novel biomarker associated with ferroptosis and the tumor microenvironment: a pancancer analysis.","date":"2023","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/37566748","citation_count":15,"is_preprint":false},{"pmid":"37207473","id":"PMC_37207473","title":"lncRNA SYTL5-OT4 promotes vessel co-option by inhibiting the autophagic degradation of ASCT2.","date":"2023","source":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/37207473","citation_count":15,"is_preprint":false},{"pmid":"34811815","id":"PMC_34811815","title":"Circ_0000463 contributes to the progression and glutamine metabolism of non-small-cell lung cancer by targeting miR-924/SLC1A5 signaling.","date":"2021","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/34811815","citation_count":15,"is_preprint":false},{"pmid":"35567340","id":"PMC_35567340","title":"Circ_0001273 downregulation inhibits the growth, migration and glutamine metabolism of esophageal cancer cells via targeting the miR-622/SLC1A5 signaling axis.","date":"2022","source":"Thoracic cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35567340","citation_count":15,"is_preprint":false},{"pmid":"39696988","id":"PMC_39696988","title":"ATF4 promotes glutaminolysis and glycolysis in colorectal cancer by transcriptionally inducing SLC1A5.","date":"2024","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/39696988","citation_count":14,"is_preprint":false},{"pmid":"34171602","id":"PMC_34171602","title":"Comprehensive molecular and clinical characterization of SLC1A5 in human cancers.","date":"2021","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/34171602","citation_count":14,"is_preprint":false},{"pmid":"35284960","id":"PMC_35284960","title":"Circ_0062558 promotes growth, migration, and glutamine metabolism in triple-negative breast cancer by targeting the miR-876-3p/SLC1A5 axis.","date":"2022","source":"Archives of gynecology and obstetrics","url":"https://pubmed.ncbi.nlm.nih.gov/35284960","citation_count":14,"is_preprint":false},{"pmid":"12555937","id":"PMC_12555937","title":"Hartnup disorder: polymorphisms identified in the neutral amino acid transporter SLC1A5.","date":"2002","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/12555937","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52740,"output_tokens":8509,"usd":0.142928,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18442,"output_tokens":7010,"usd":0.13373,"stage2_stop_reason":"end_turn"},"total_usd":0.276658,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2018,\n      \"finding\": \"Cryo-EM and crystal structures of ASCT2/SLC1A5 revealed that substrate recognition involves conformational changes in the HP2 loop, the ECL2a loop connects the scaffold and transport domains enabling rigid body movement during the transport cycle, and a putative cholesterol binding site exists near the domain interface in the outward-facing state. Comparison with the inward-facing structure provided a mechanistic basis for the transport cycle.\",\n      \"method\": \"Cryo-EM structure determination; substrate co-complex structures\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cryo-EM structures of human SLC1A5 in outward-facing conformation with and without substrate, multiple orthogonal structural approaches\",\n      \"pmids\": [\"31580259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Crystal structures of a prokaryotic ASCT2 homologue bearing mutations at two substrate-binding residues identified in ASCT2 revealed the structural basis for glutamine (neutral amino acid) selectivity and inhibitor binding in the SLC1 family; these two residues confer glutamine selectivity unique to ASCT2 among SLC1 family members.\",\n      \"method\": \"Site-directed mutagenesis of substrate-binding residues; crystal structure determination of prokaryotic homologue\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — four crystal structures with mutagenesis validating functional relevance of identified residues\",\n      \"pmids\": [\"29295993\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Rational design using cryo-EM structures and molecular dynamics simulations identified stereospecific ASCT2 inhibitors exploiting specific subpockets in the substrate binding site, revealing multiple pharmacologically relevant conformations and a previously unknown mechanism of stereospecific inhibition.\",\n      \"method\": \"Cryo-EM; molecular dynamics simulations; electrophysiology transport assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — integrated cryo-EM structures with MD simulations and functional validation of inhibitor mechanism\",\n      \"pmids\": [\"34507995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Purified human ASCT2 reconstituted in proteoliposomes demonstrated Na+-dependent glutamine/glutamine antiport activity with functional and kinetic asymmetry: external Km for glutamine (0.097 mM) was ~18-fold lower than internal Km (1.8 mM); Ala, Cys, Val, Met were only inwardly transported while Gln, Ser, Asn, Thr were transported bi-directionally. Cys395 was identified as the only externally exposed cysteine and potential target of SH-reagent inhibition.\",\n      \"method\": \"Recombinant protein expression in Pichia pastoris; reconstitution in proteoliposomes; radiolabeled transport assays; homology modeling\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with detailed kinetic characterization, replicated in subsequent studies\",\n      \"pmids\": [\"23756778\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Kinetic analysis of purified ASCT2 in proteoliposomes established a random simultaneous transport mechanism for the Na+-glutamine antiport reaction. The transporter was cross-linked to a stable dimeric form. The transport reaction is electrogenic, with electrogenicity originating from external Na+. Internal Na+ exerts a stimulatory regulatory (not counter-transport) effect. PDZK1 scaffold protein interaction with hASCT2 was confirmed both in vitro and in vivo.\",\n      \"method\": \"Pseudo-bi-substrate kinetic analysis in proteoliposomes; chemical cross-linking; membrane potential imposition with valinomycin; co-immunoprecipitation\",\n      \"journal\": \"Amino acids\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with multiple mechanistic assays (kinetics, electrogenicity, oligomeric state, protein interaction) in single study\",\n      \"pmids\": [\"25052780\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Site-directed mutagenesis of all cysteine residues in hASCT2 identified Cys467 as critical for substrate binding and transport activity modulation: C467A mutant showed ~10-fold higher Km for glutamine and lost sensitivity to both DTE activation and methylmercury inhibition. Cys467 is located in the substrate binding region based on structural comparison with EAAT1.\",\n      \"method\": \"Cys-to-Ala site-directed mutagenesis; transport assays in proteoliposomes; bioinformatics structural comparison\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic mutagenesis of all 8 Cys residues with functional assays in reconstituted system, single lab\",\n      \"pmids\": [\"29495336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"N-linked glycosylation at Asn163 and Asn212 is critical for ASCT2 trafficking to the plasma membrane. Double mutation N163/212Q produced unglycosylated protein that failed to traffic to the membrane, showed strongly increased endocytosis rate, and reduced transport activity in intact cells. Critically, intrinsic transport function of the mutant was not affected when reconstituted in liposomes, demonstrating glycosylation regulates membrane localization rather than transport mechanism per se.\",\n      \"method\": \"Site-directed mutagenesis; protein biotinylation assay; reversible biotinylation endocytosis assay; cycloheximide stability assay; brefeldin-based trafficking assay; radiolabeled transport assay in cells and proteoliposomes\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods in one study clearly dissecting glycosylation roles in trafficking vs. transport function\",\n      \"pmids\": [\"25862406\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A variant of SLC1A5 with an N-terminal mitochondrial targeting signal localizes to mitochondria and transports glutamine into mitochondria. HIF-2α mediates hypoxia-induced expression of this variant. Overexpression promotes glutamine-induced ATP production and glutathione synthesis, and confers gemcitabine resistance in pancreatic cancer cells.\",\n      \"method\": \"Mitochondrial fractionation; live-cell imaging; siRNA knockdown; metabolic assays; HIF-2α ChIP; xenograft models\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — subcellular fractionation plus functional assays demonstrating mitochondrial localization and consequences, multiple orthogonal methods\",\n      \"pmids\": [\"31866442\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Cholesterol stimulates ASCT2 transport activity by ~3-fold increase in Vmax without affecting Km for glutamine. Cholesterol physically binds to the protein near CARC/CRAC motifs and tryptophan residues; modification of tryptophan residues blocked cholesterol binding, and cholesterol presence impaired thiol reagent access to cysteines.\",\n      \"method\": \"Transport assays in proteoliposomes with cholesteryl hemisuccinate; computational docking; tryptophan modification; thiol-reagent competition assays\",\n      \"journal\": \"Frontiers in molecular biosciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro reconstitution with docking, but single lab and indirect binding evidence\",\n      \"pmids\": [\"31709262\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"A hypervariable 21-amino acid sequence in the carboxyl-terminal portion of extracellular loop 2 (ECL2) of hASCT2 is critical for retroviral receptor function for RD114, BaEV, HERV-W, and type D primate retroviruses. N-linked oligosaccharides in the carboxyl-terminal region of ECL2 restrict viral infections; tunicamycin (N-glycosylation inhibitor) treatment or mutagenesis of N-glycosylation sites activated receptor function for all viruses in the interference group.\",\n      \"method\": \"hASCT2/mASCT2 chimera construction; site-directed mutagenesis; viral infection susceptibility assays; tunicamycin treatment\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic chimera and mutagenesis analysis with functional viral infection readouts, multiple constructs tested\",\n      \"pmids\": [\"12584318\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The truncated ASCT2 mRNA isoform encodes multiple protein isoforms with distinct amino termini initiated by leaky scanning at CUG and GUG codons. ASCT2 isoforms with short N-terminal truncations retained both amino acid transport and viral receptor activities, whereas an isoform lacking the first transmembrane domain (79-aa truncation) retained only viral receptor activity but not amino acid transport activity.\",\n      \"method\": \"Site-directed mutagenesis of initiation codons; cell-free translation; epitope-tagged protein analysis; amino acid transport assay; viral infection assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — deletion and site-directed mutagenesis with multiple functional readouts dissecting domains required for transport vs. receptor activity\",\n      \"pmids\": [\"11350958\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ASCT2 (SLC1A5) is physically associated with EGFR in a molecular complex in HNSCC cells. Cetuximab-mediated EGFR endocytosis downregulates ASCT2 in an EGFR expression-dependent manner, decreasing glutamine uptake and glutathione levels, thereby sensitizing cells to ROS-induced apoptosis. EGFR kinase inhibition (gefitinib) or siRNA knockdown of EGFR failed to sensitize cells to ROS-induced apoptosis.\",\n      \"method\": \"Co-immunoprecipitation; EGFR endocytosis assay; glutamine uptake assay; glutathione measurement; apoptosis assay; siRNA knockdown\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — reciprocal Co-IP showing complex with functional consequences, single lab\",\n      \"pmids\": [\"27450723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"DDR1 (discoidin domain receptor 1) interacts with SLC1A5 and regulates its protein stability through lysosome-dependent degradation. Loss of DDR1 decreased SLC1A5 levels and downstream mTORC1 signaling; lysosome inhibitors restored SLC1A5 regulation by DDR1.\",\n      \"method\": \"Co-immunoprecipitation; CHX stability assay; lysosomal inhibitor (NH4Cl) rescue; mTORC1 signaling assessment; xenograft model\",\n      \"journal\": \"Cellular oncology (Dordrecht, Netherlands)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP with functional stability assays, single lab, identifies lysosomal degradation mechanism\",\n      \"pmids\": [\"35089546\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TRIM6 E3 ubiquitin ligase directly interacts with SLC1A5 and promotes its ubiquitination and proteasomal degradation, thereby inhibiting glutamine import, glutaminolysis, lipid peroxidation, and ferroptosis in lung cancer cells.\",\n      \"method\": \"Co-immunoprecipitation; ubiquitination assay; TRIM6 overexpression/knockdown; glutamine uptake assay; ferroptosis assays; xenograft model\",\n      \"journal\": \"Oxidative medicine and cellular longevity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP and ubiquitination assays establish E3-substrate relationship, single lab\",\n      \"pmids\": [\"36654781\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ASCT2 in astrocytes binds to NLRP3 and aggravates astrocytic inflammasome-triggered neuroinflammation in Parkinson's disease models. Genetic ablation of astrocytic ASCT2 alleviated neuroinflammation and rescued dopaminergic neuron damage in vitro and in vivo.\",\n      \"method\": \"Co-immunoprecipitation (ASCT2-NLRP3 binding); conditional knockout in astrocytes; MPTP mouse model; in vitro MPP+/LPS-ATP challenge\",\n      \"journal\": \"Acta pharmaceutica Sinica. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP demonstrating ASCT2-NLRP3 complex with genetic loss-of-function phenotype, single lab\",\n      \"pmids\": [\"36873178\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Inhibition of ASCT2 induces hepatic stellate cell senescence by interfering with the IL-1α/NF-κB feedback loop; ASCT2 physically interacts with precursor IL-1α at Lys82 and is a direct target of glutaminolysis-dependent proinflammatory SASP signaling.\",\n      \"method\": \"Co-immunoprecipitation (ASCT2-pro-IL-1α interaction); genetic ASCT2 inhibition; in vitro senescence assays; mouse fibrosis model\",\n      \"journal\": \"Acta pharmaceutica Sinica. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP identifies ASCT2-IL-1α interaction, single lab with multiple readouts but not replicated\",\n      \"pmids\": [\"36176909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CAIX (carbonic anhydrase IX) physically interacts with SLC1A5 and coordinately regulates redox homeostasis through the GSH/GPX4 axis. Inhibition of CAIX increases glutamine uptake via SLC1A5 and raises GSH levels; combined inhibition of CAIX and SLC1A5/glutamine metabolism induces ferroptosis in vitro and in vivo.\",\n      \"method\": \"Co-immunoprecipitation; glutamine uptake assays; GSH/lipid peroxidation measurements; in vivo tumor models\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP establishing CAIX-SLC1A5 complex with functional consequence, single lab\",\n      \"pmids\": [\"37348875\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Deletion of ASCT2 (SLC1A5) in HeLa and 143B cancer cells did not reduce net glutamine uptake or cell growth; instead, it activated a GCN2-dependent amino acid starvation response that upregulated SNAT1 (SLC38A1) to compensate. Combined silencing of GCN2 in the ASCT2-/- background reduced cell growth, demonstrating that net glutamine uptake requires SNAT1/SNAT2, not ASCT2 in these cell lines.\",\n      \"method\": \"CRISPR/TALEN-mediated ASCT2 deletion; radiolabeled amino acid uptake; GCN2 siRNA; growth assays; Western blot for stress response markers\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic deletion with epistasis analysis (GCN2 double knockout rescue), multiple orthogonal methods, replicated in subsequent work\",\n      \"pmids\": [\"27129276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ASCT2 KO in colon (LS174T) and lung (A549) cancer cells reduced glutamine import by >60% but did not affect leucine uptake. ASCT2 KO strongly decreased tumor growth in vivo in both lines, but without triggering amino acid stress response (GCN2/EIF2α/ATF4) or altered mTORC1 (S6K1/S6) activity in contrast to LAT1 KO cells, indicating ASCT2-mediated tumor growth reduction is independent of LAT1 and independent of mTORC1 modulation in these contexts.\",\n      \"method\": \"CRISPR-Cas9 knockout; radiolabeled amino acid uptake assays; Western blot for mTORC1/GCN2 signaling; xenograft tumor models\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR KO in two cell lines with in vivo validation and pathway analysis, multiple orthogonal methods\",\n      \"pmids\": [\"29326164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"STAT3 regulates MYC expression in AML leukemia stem cells, which directly controls SLC1A5 transcription. Genetic inhibition of MYC or SLC1A5 phenocopied STAT3 inhibition in impairing oxidative phosphorylation. SLC1A5 inhibition reduced intracellular glutamine, glutathione, and TCA cycle metabolites, leading to reduced TCA cycle activity and OXPHOS inhibition.\",\n      \"method\": \"Genetic inhibition (shRNA/siRNA) of STAT3, MYC, and SLC1A5; metabolomics; OXPHOS measurement; primary human AML specimens\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis establishing STAT3→MYC→SLC1A5 axis with metabolic readouts in primary human specimens and multiple genetic approaches\",\n      \"pmids\": [\"34525179\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ATF4 and N-Myc coordinately activate ASCT2 transcription in MYCN-amplified neuroblastoma cells. ATF4 was identified as a novel regulator directly binding the ASCT2 promoter region to activate its expression in cooperation with N-Myc.\",\n      \"method\": \"ChIP; luciferase reporter assay; ASCT2 depletion with glutaminolysis measurement; proliferation/tumorigenesis assays\",\n      \"journal\": \"The Journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ChIP and luciferase reporter establish direct transcriptional activation, single lab\",\n      \"pmids\": [\"25142020\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SLC1A5 is a direct transcriptional target of c-Myc. Myc+/- heterozygous mice have decreased Slc1a5 expression, lower glutamine uptake, reduced mTORC1 activity, and elevated fatty acid oxidation via Cpt1a upregulation, establishing MYC→SLC1A5→mTORC1→FAO as a regulatory axis.\",\n      \"method\": \"Gene expression analysis in Myc+/- mice; glutamine uptake assays; mTORC1 activity measurement; Cpt1a expression analysis; ChIP (MYC binding to SLC1A5 promoter implied by prior work)\",\n      \"journal\": \"Aging cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — genetic model with multiple metabolic readouts, single lab, limited direct mechanistic validation of MYC-SLC1A5 promoter binding\",\n      \"pmids\": [\"30909319\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ATF4 directly activates SLC1A5 transcription in colorectal cancer cells, as demonstrated by increased luciferase activity of the SLC1A5 promoter upon ATF4 overexpression and increased SLC1A5 promoter enrichment in ChIP with anti-ATF4 antibody. SLC1A5 knockdown inhibited glutamine metabolism, glucose metabolism, and expression of glycolytic enzymes HK2 and PKM2.\",\n      \"method\": \"Luciferase reporter assay; chromatin immunoprecipitation (ChIP); ATF4 overexpression/knockdown; SLC1A5 knockdown with metabolic assays\",\n      \"journal\": \"Acta biochimica et biophysica Sinica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ChIP and luciferase reporter establish direct transcriptional regulation, single lab\",\n      \"pmids\": [\"39696988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MeCP2 and DNA methyltransferases (DNMTs) cooperate to methylate the miR-137 promoter, repressing miR-137 transcription and thereby derepressing ASCT2 expression and glutamine metabolism in cancer cells. miR-137 directly targets the ASCT2 3'UTR. Ectopic ASCT2 expression rescued miR-137-mediated suppression of tumorigenesis.\",\n      \"method\": \"Promoter methylation analysis; ChIP; miR-137 overexpression/knockdown; ASCT2 rescue experiments; glutamine metabolic analysis\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — multiple methods establishing epigenetic regulatory mechanism, single lab\",\n      \"pmids\": [\"28692032\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"miR-137 negatively regulates ferroptosis by directly targeting SLC1A5, suppressing glutamine uptake and malondialdehyde accumulation. Ectopic miR-137 expression decreased SLC1A5 levels and reduced sensitivity to ferroptosis inducers erastin and RSL3 in melanoma cells.\",\n      \"method\": \"miR-137 ectopic expression; antagomir treatment; SLC1A5 3'UTR luciferase reporter; glutamine uptake; MDA measurement; in vivo xenograft\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct targeting validated by luciferase reporter with functional ferroptosis readouts, single lab\",\n      \"pmids\": [\"29348676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"GLAST/EAAT1-mediated glutamate uptake into astrocytes, when converted to glutamine by glutamine synthetase (GS), is a potent inducer of ASCT2 trafficking from cytosol to the plasma membrane. In differentiated human fetal astrocytes, glutamine (and to a lesser extent alanine) redistributed ASCT2 from cytosol to membrane; at lower pH (6.2–6.7), the cell surface pool of ASCT2 was larger. GS knockdown abolished the glutamate-induced effect on ASCT2 trafficking.\",\n      \"method\": \"siRNA knockdown of GS; immunofluorescence/subcellular localization of ASCT2; amino acid transport assays in human fetal astrocyte cultures; cAMP-induced differentiation\",\n      \"journal\": \"Neurochemistry international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — siRNA epistasis with immunofluorescence establishing substrate-dependent trafficking mechanism, single lab\",\n      \"pmids\": [\"16516348\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ASCT2 promoter activity and protein expression in HepG2 hepatoma cells are dependent on glutamine availability: glutamine deprivation reduced both ASCT2 protein and promoter-driven luciferase activity; restoration of glutamine reversed these effects. Deprivation of other essential amino acids had no effect on promoter activity.\",\n      \"method\": \"Luciferase reporter assay with 907-bp ASCT2 5'-flanking sequence; Western blot for ASCT2 protein; glutamine deprivation/repletion experiments\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — luciferase reporter assay establishing glutamine-dependent promoter regulation, single lab\",\n      \"pmids\": [\"15175006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ASCT2 (SLC1A5) functions as a major serine transporter in cancer cells, with serine and glutamine competing for uptake through ASCT2. ASCT2-mediated serine uptake is essential for purine nucleotide biosynthesis. Estrogen receptor α (ERα) promotes serine uptake by directly activating SLC1A5 transcription.\",\n      \"method\": \"ASCT2 knockout/knockdown; serine uptake assays; glutamine/serine competition assays; purine biosynthesis metabolomics; ERα ChIP on SLC1A5 promoter\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ASCT2 KO with multiple functional readouts (serine transport, purine biosynthesis, ERα ChIP), multiple orthogonal methods\",\n      \"pmids\": [\"39068660\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SLC1A5 provides both glutamine and asparagine to osteoblasts, which are essential for osteoblast differentiation. These amino acids primarily support biosynthesis of non-essential amino acids. Cell-autonomous loss of SLC1A5 impaired protein synthesis and osteoblast differentiation in a genetic mouse model.\",\n      \"method\": \"Conditional osteoblast-specific Slc1a5 knockout; metabolomic analysis; protein synthesis assays; differentiation assays\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type specific genetic knockout with metabolomics and multiple functional readouts establishing mechanism\",\n      \"pmids\": [\"34647520\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Slc1a5 (ASCT2) knockout mice showed mild hematopoietic defects under steady state but reduced leukemia initiation and maintenance driven by MLL-AF9 or Pten deficiency. Loss of ASCT2 disrupted leucine influx and mTOR signaling and induced apoptosis in leukemic cells. Pharmacological ASCT2 inhibition decreased human AML xenograft growth.\",\n      \"method\": \"Constitutive and inducible Slc1a5 knockout mice; MLL-AF9 and Pten-deficiency leukemia models; metabolomics; mTOR signaling assessment; xenograft models\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic knockout in two leukemia models with mechanistic metabolic analysis, multiple approaches\",\n      \"pmids\": [\"31535081\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"V-9302, a competitive small molecule antagonist, selectively and potently inhibits ASCT2-mediated glutamine transport. Pharmacological ASCT2 blockade by V-9302 attenuated cancer cell growth, increased cell death, and increased oxidative stress, contributing to antitumor responses in vitro and in vivo.\",\n      \"method\": \"Competitive transport inhibition assays; glutamine uptake measurement; cancer cell proliferation/death assays; ROS measurement; xenograft tumor models\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — competitive inhibition demonstrated biochemically with in vitro and in vivo validation, high-impact journal\",\n      \"pmids\": [\"29334372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Mettl3-mediated m6A modification of Slc1a5 mRNA is recognized by Igf2bp2, which stabilizes the mRNA and promotes osteoblast senescence. Inhibition of Mettl3 reduced Slc1a5 m6A modification and expression, reducing osteoblast senescence and age-related bone loss in rats.\",\n      \"method\": \"m6A-RIP; Mettl3/Igf2bp2 overexpression/knockdown; mRNA stability assays; Cpd-564 (Mettl3 inhibitor) treatment; siRNA in vivo delivery; aged rat and OVX rat models\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — m6A-RIP establishes modification, multiple genetic approaches, single lab\",\n      \"pmids\": [\"38844111\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"lncRNA SYTL5-OT4 enhances ASCT2 protein expression by inhibiting its autophagic degradation. SYTL5-OT4 interacts with ASCT2, and this interaction protects ASCT2 from autophagy-mediated degradation; ASCT2 promotes vessel co-option and tumor cell proliferation/EMT in colorectal cancer liver metastasis.\",\n      \"method\": \"RNA immunoprecipitation; co-immunoprecipitation; loss/gain-of-function experiments; autophagic flux assays; histological analysis\",\n      \"journal\": \"Drug resistance updates\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — RIP and Co-IP establish SYTL5-OT4/ASCT2 interaction with autophagic degradation assays, single lab\",\n      \"pmids\": [\"37207473\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SLC1A5/ASCT2 is a sodium-dependent, electrogenic neutral amino acid antiporter that resides primarily at the plasma membrane (with a mitochondria-targeted variant) and mediates Na+-coupled obligatory exchange of glutamine, serine, asparagine, alanine, cysteine, and threonine; its transport domain undergoes rigid-body movements enabled by the ECL2a linker and HP2-loop conformational changes (established by cryo-EM and crystal structures), substrate selectivity for glutamine is conferred by two specific binding-site residues, Cys467 is critical for substrate binding and redox regulation, and N-glycosylation at Asn163/Asn212 governs plasma membrane trafficking rather than intrinsic transport activity; transcription is directly activated by MYC, ATF4, N-Myc, and ERα, repressed via miR-137 (itself silenced by MeCP2/DNMT-mediated methylation), and the protein is stabilized or degraded through interactions with DDR1, TRIM6 (ubiquitin-E3 ligase), or autophagic machinery, while functionally it supplies glutamine and serine to support TCA cycle anaplerosis, mTORC1 activation, glutathione synthesis, purine biosynthesis, and OXPHOS, making it a context-dependent but frequently essential driver of cancer cell proliferation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"SLC1A5 (ASCT2) is a sodium-dependent neutral amino acid antiporter that supplies glutamine and other neutral amino acids to fuel cancer cell metabolism, supporting TCA-cycle anaplerosis, mTOR signaling, redox balance, and biosynthesis [#3, #19, #27]. In reconstituted proteoliposomes the purified transporter performs Na+-coupled obligatory exchange with marked kinetic asymmetry, transporting Gln, Ser, Asn, and Thr bidirectionally while moving Ala, Cys, Val, and Met inward only, operating via a random simultaneous mechanism that is electrogenic from external Na+ [#3, #4]. Cryo-EM and crystal structures define the transport cycle: substrate recognition involves HP2-loop conformational change, the ECL2a loop links scaffold and transport domains to permit rigid-body movement, and two substrate-binding residues confer the glutamine selectivity unique to ASCT2 within the SLC1 family [#0, #1]. Cys467 is critical for substrate binding and for redox/thiol modulation of activity, and cholesterol stimulates transport by increasing Vmax [#5, #8], while N-glycosylation at Asn163/Asn212 governs plasma-membrane trafficking rather than intrinsic transport function [#6]. Beyond its canonical plasma-membrane role, an N-terminally extended, HIF-2\\u03b1-induced variant targets mitochondria to import glutamine and drive ATP and glutathione production [#7], and ASCT2 additionally functions as a major serine transporter feeding purine biosynthesis [#27]. Transcription is driven by MYC/N-Myc, ATF4, and ER\\u03b1 [#19, #20, #22, #27] and derepressed by loss of miR-137 [#23, #24], while protein abundance is set by interacting partners that promote degradation (TRIM6-mediated ubiquitination, DDR1-linked lysosomal turnover) or stabilization (lncRNA SYTL5-OT4 blocking autophagic degradation) [#12, #13, #32]. Genetic ablation across leukemia, colon, lung, and osteoblast models demonstrates ASCT2-dependent glutamine/serine/asparagine supply, mTOR signaling, OXPHOS, and proliferation, although in some cell lines net glutamine uptake is compensated by SNAT transporters via a GCN2-dependent stress response, making ASCT2 a context-dependent driver of growth [#17, #18, #19, #28, #29]. ASCT2 also serves as a receptor for several retroviruses through a hypervariable ECL2 segment whose N-glycans restrict viral entry [#9, #10].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Resolved which structural elements of ASCT2 are required for amino acid transport versus retroviral receptor function, separating its two activities.\",\n      \"evidence\": \"Initiation-codon mutagenesis and cell-free translation generating N-terminal truncation isoforms tested in transport and infection assays\",\n      \"pmids\": [\"11350958\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the full transport mechanism\", \"Physiological role of leaky-scanning isoforms unclear\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Mapped the determinant of ASCT2 retroviral receptor function and showed N-glycans on ECL2 restrict viral entry.\",\n      \"evidence\": \"Human/mouse chimeras, glycosylation-site mutagenesis, and tunicamycin treatment with viral susceptibility readouts\",\n      \"pmids\": [\"12584318\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address endogenous transport consequences of these residues\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Showed ASCT2 expression is feedback-regulated by its own substrate, linking glutamine availability to transporter abundance.\",\n      \"evidence\": \"ASCT2 promoter luciferase reporter plus Western blot under glutamine deprivation/repletion in hepatoma cells\",\n      \"pmids\": [\"15175006\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcription factor mediating glutamine sensing not identified\", \"Single cell line\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Established that substrate supply drives ASCT2 relocation to the plasma membrane, coupling astrocytic glutamate metabolism to transporter surface expression.\",\n      \"evidence\": \"GS siRNA knockdown with immunofluorescence and transport assays in human fetal astrocytes\",\n      \"pmids\": [\"16516348\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Trafficking machinery undefined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Provided the first quantitative mechanism of human ASCT2 as an asymmetric Na+-dependent obligatory antiporter with distinct substrate directionality.\",\n      \"evidence\": \"Recombinant protein reconstituted in proteoliposomes with radiolabeled transport kinetics\",\n      \"pmids\": [\"23756778\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic structure not yet resolved\", \"Functional role of externally exposed cysteine inferred not proven\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined the kinetic mechanism, electrogenicity, oligomeric state, and a scaffold partner of ASCT2.\",\n      \"evidence\": \"Pseudo-bi-substrate kinetics, cross-linking, valinomycin membrane-potential assays, and PDZK1 co-IP\",\n      \"pmids\": [\"25052780\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological significance of PDZK1 interaction not established\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified ATF4 and N-Myc as direct transcriptional activators coupling oncogenic signaling to ASCT2 expression.\",\n      \"evidence\": \"ChIP and luciferase reporter assays with depletion and proliferation readouts in neuroblastoma\",\n      \"pmids\": [\"25142020\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Cooperativity mechanism between ATF4 and N-Myc not detailed\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Separated the role of N-glycosylation in membrane trafficking from intrinsic transport activity.\",\n      \"evidence\": \"N163/212Q mutagenesis with biotinylation, endocytosis, stability, and reconstituted transport assays\",\n      \"pmids\": [\"25862406\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trafficking/endocytic machinery downstream of glycan loss undefined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Tested whether ASCT2 is the obligate glutamine transporter and revealed compensatory redundancy via a GCN2-driven stress response.\",\n      \"evidence\": \"CRISPR/TALEN ASCT2 deletion with GCN2 epistasis and amino acid uptake assays\",\n      \"pmids\": [\"27129276\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Context-dependence across cell types not fully mapped\", \"Did not test in vivo tumors\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Linked ASCT2 to EGFR in a complex governing glutamine-dependent redox protection.\",\n      \"evidence\": \"Co-IP, EGFR endocytosis, glutamine uptake, glutathione, and apoptosis assays in HNSCC\",\n      \"pmids\": [\"27450723\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect EGFR-ASCT2 interaction not resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established an epigenetic-microRNA axis (MeCP2/DNMT-miR-137) controlling ASCT2 expression in cancer.\",\n      \"evidence\": \"Promoter methylation analysis, ChIP, miR-137 modulation, and ASCT2 3'UTR rescue\",\n      \"pmids\": [\"28692032\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Generality across tumor types unverified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Delivered atomic structures defining the ASCT2 transport cycle and the structural basis of glutamine selectivity and inhibitor binding.\",\n      \"evidence\": \"Cryo-EM of human ASCT2 and crystal structures of a prokaryotic homologue with substrate-binding mutagenesis\",\n      \"pmids\": [\"31580259\", \"29295993\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Conformational dynamics in lipid bilayers not directly captured\", \"Cholesterol site functional role addressed separately\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified Cys467 as a substrate-binding residue mediating redox modulation of ASCT2 activity.\",\n      \"evidence\": \"Systematic Cys-to-Ala mutagenesis with transport assays in proteoliposomes\",\n      \"pmids\": [\"29495336\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological redox signals acting on Cys467 in cells not defined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated ASCT2 KO reduces glutamine import and tumor growth independent of LAT1 and mTORC1 in certain contexts, refining its role.\",\n      \"evidence\": \"CRISPR-Cas9 KO in colon and lung lines with uptake, signaling, and xenograft assays\",\n      \"pmids\": [\"29326164\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of growth dependence without mTORC1 change unexplained\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Validated ASCT2 as a druggable target with a competitive small-molecule antagonist showing antitumor activity.\",\n      \"evidence\": \"V-9302 competitive inhibition, glutamine uptake, ROS, and xenograft assays\",\n      \"pmids\": [\"29334372\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Selectivity later debated; on-target specificity not addressed here\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Connected ASCT2 to ferroptosis regulation via miR-137 targeting.\",\n      \"evidence\": \"miR-137 modulation, 3'UTR luciferase, glutamine uptake, MDA, and ferroptosis-inducer assays in melanoma\",\n      \"pmids\": [\"29348676\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Quantitative contribution to ferroptosis vs other regulators unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Discovered a mitochondria-targeted ASCT2 variant supplying intramitochondrial glutamine for ATP and glutathione, regulated by hypoxia.\",\n      \"evidence\": \"Mitochondrial fractionation, imaging, siRNA, metabolic assays, HIF-2\\u03b1 ChIP, and xenografts\",\n      \"pmids\": [\"31866442\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of dual targeting (PM vs mitochondria) not fully defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established MYC as a direct activator of SLC1A5 coupling it to mTORC1 and fatty acid oxidation in vivo.\",\n      \"evidence\": \"Myc+/- mouse gene expression, glutamine uptake, mTORC1 and Cpt1a analyses\",\n      \"pmids\": [\"30909319\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct MYC promoter binding inferred from prior work\", \"Single lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrated in vivo that ASCT2 supports leukemia initiation/maintenance via leucine influx and mTOR signaling.\",\n      \"evidence\": \"Constitutive/inducible Slc1a5 KO mice in MLL-AF9 and Pten leukemia models with metabolomics and xenografts\",\n      \"pmids\": [\"31535081\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking ASCT2 to leucine influx not fully resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined the physiological requirement for ASCT2 in osteoblast differentiation via glutamine/asparagine supply.\",\n      \"evidence\": \"Osteoblast-specific Slc1a5 KO with metabolomics and protein-synthesis/differentiation assays\",\n      \"pmids\": [\"34647520\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specificity of dependence not generalized\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Enabled structure-guided design of stereospecific ASCT2 inhibitors and revealed multiple pharmacological conformations.\",\n      \"evidence\": \"Cryo-EM, molecular dynamics, and electrophysiology transport assays\",\n      \"pmids\": [\"34507995\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo efficacy of designed inhibitors not assessed here\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified TRIM6 as an E3 ligase degrading ASCT2 to restrain glutaminolysis and ferroptosis.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, glutamine uptake, ferroptosis, and xenograft models in lung cancer\",\n      \"pmids\": [\"36654781\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Ubiquitination site on ASCT2 not mapped\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified DDR1 as a regulator of ASCT2 stability via lysosomal degradation feeding mTORC1.\",\n      \"evidence\": \"Co-IP, CHX stability, lysosomal-inhibitor rescue, and xenograft assays\",\n      \"pmids\": [\"35089546\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Mechanism of DDR1-directed lysosomal routing unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Placed STAT3->MYC->SLC1A5 as a transcriptional axis sustaining OXPHOS in leukemia stem cells.\",\n      \"evidence\": \"Genetic inhibition of STAT3/MYC/SLC1A5 with metabolomics and OXPHOS measurement in primary AML\",\n      \"pmids\": [\"34525179\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct STAT3 occupancy of MYC locus not detailed in this entry\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed non-transport scaffolding roles of ASCT2 in inflammatory signaling through NLRP3 and pro-IL-1\\u03b1 binding.\",\n      \"evidence\": \"Co-IP, astrocytic conditional KO/MPTP and hepatic stellate cell senescence models\",\n      \"pmids\": [\"36873178\", \"36176909\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single labs\", \"Direct vs transport-dependent contributions to phenotypes not fully separated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed CAIX physically partners with SLC1A5 to coordinate redox homeostasis via the GSH/GPX4 axis.\",\n      \"evidence\": \"Co-IP, glutamine uptake, GSH/lipid peroxidation, and in vivo tumor models\",\n      \"pmids\": [\"37348875\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Structural basis of CAIX-SLC1A5 interaction unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified lncRNA SYTL5-OT4 as a stabilizer of ASCT2 protein by blocking its autophagic degradation in metastasis.\",\n      \"evidence\": \"RIP, Co-IP, autophagic flux, and loss/gain-of-function in colorectal liver metastasis\",\n      \"pmids\": [\"37207473\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Mechanism of autophagy targeting of ASCT2 unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Established ASCT2 as a major serine transporter feeding purine biosynthesis and identified ER\\u03b1 as a direct transcriptional activator.\",\n      \"evidence\": \"ASCT2 KO/KD with serine uptake, glutamine/serine competition, purine metabolomics, and ER\\u03b1 ChIP\",\n      \"pmids\": [\"39068660\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative physiological balance of serine vs glutamine transport in vivo unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Added ATF4 as a direct activator of SLC1A5 linking it to glucose and glycolytic enzyme regulation in colorectal cancer.\",\n      \"evidence\": \"Luciferase reporter, ChIP, and SLC1A5 knockdown metabolic assays\",\n      \"pmids\": [\"39696988\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Mechanism linking ASCT2 to HK2/PKM2 expression unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed m6A modification stabilizes Slc1a5 mRNA to drive osteoblast senescence and bone loss.\",\n      \"evidence\": \"m6A-RIP, Mettl3/Igf2bp2 modulation, mRNA stability, inhibitor and aged/OVX rat models\",\n      \"pmids\": [\"38844111\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"m6A sites on Slc1a5 not precisely mapped\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How transport-dependent and transport-independent (scaffolding) functions of ASCT2 are integrated, and what determines its context-dependent essentiality across tissues, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model reconciling redundant vs essential glutamine uptake across cell types\", \"Mechanism of dual PM/mitochondrial targeting undefined\", \"Transport-independent inflammatory roles mechanistically unexplained\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [3, 4, 18, 27, 30]},\n      {\"term_id\": \"GO:0140104\", \"supporting_discovery_ids\": [3, 7, 27]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [9, 10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [6, 25]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [25]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [3, 4, 27]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [7, 19, 27, 28]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [13, 24]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"PDZK1\", \"EGFR\", \"DDR1\", \"TRIM6\", \"NLRP3\", \"IL1A\", \"CA9\"],\n    \"other_free_text\": []\n  }\n}\n```","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}